Author: Editor

Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage breast cancer in the United States and not in other countries? I’m talking about our study looking at patterns of adjuvant bone modifying use in patients with early stage breast cancers. Bone modifying agents, particularly bisphosphonates, not only help preserve bone density (or bone material loss) in postmenopausal women receiving endocrine therapy for treatment of breast cancer, but we also know that they reduce the risk of breast cancer recurrence as well as reduce the risk of breast cancer specific…

Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab either with our without Bendamustine show in this clinical trial? So our study is a retrospective study of patients treated with Polatuzumab Vedotin which is a CD79 antibody drug conjugate in combination with Rituximab plus the addition of Bendamustine in the patient population with relapsed refractory large b-cell lymphoma (RR DLBCL). Our aim was to analyze the institutional outcomes of patients treated with this regimen. And as well, we wanted to look at the pattern of failure to front-line therapy,…

iFrame is not supported! Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab either with our without Bendamustine show in this clinical trial? So our study is a retrospective study of patients treated with Polatuzumab Vedotin which is a CD79 antibody drug conjugate in combination with Rituximab plus the addition of Bendamustine in the patient population with relapsed refractory large b-cell lymphoma (RR DLBCL). Our aim was to analyze the institutional outcomes of patients treated with this regimen. And as well, we wanted to look at the pattern of…

Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab either with our without Bendamustine show in this clinical trial? So our study is a retrospective study of patients treated with Polatuzumab Vedotin which is a CD79 antibody drug conjugate in combination with Rituximab plus the addition of Bendamustine in the patient population with relapsed refractory large b-cell lymphoma (RR DLBCL). Our aim was to analyze the institutional outcomes of patients treated with this regimen. And as well, we wanted to look at the pattern of failure to front-line therapy,…

Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases, patients eventually may become, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for. And the reality is that complement plays…

MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up on this clinical data shown in patients with early-stage breast cancer? So this is in a real world retrospective study utilizing the 70-gene MammaPrint assay in a cohort of patients at UPMC of patients that were diagnosed with early stage breast cancer between 2005 to 2008, specifically looking at the ability to prognosticate, with regard to distant metastasis free interval, in patients that have an either low risk or high risk MammaPrint (test or genetic testing) index with the low…

iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases, patients eventually may become, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for. And the reality…

Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases, patients eventually may become, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for. And the reality is that complement plays…

iFrame is not supported! MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up on this clinical data shown in patients with early-stage breast cancer? So this is in a real world retrospective study utilizing the 70-gene MammaPrint assay in a cohort of patients at UPMC of patients that were diagnosed with early stage breast cancer between 2005 to 2008, specifically looking at the ability to prognosticate, with regard to distant metastasis free interval, in patients that have an either low risk or high risk MammaPrint (test or genetic testing)…

MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up on this clinical data shown in patients with early-stage breast cancer? So this is in a real world retrospective study utilizing the 70-gene MammaPrint assay in a cohort of patients at UPMC of patients that were diagnosed with early stage breast cancer between 2005 to 2008, specifically looking at the ability to prognosticate, with regard to distant metastasis free interval, in patients that have an either low risk or high risk MammaPrint (test or genetic testing) index with the low…

iFrame is not supported! Biomarkers: Breast Cancer – Daniel Rotroff SABCS 2022 GENIE Trial What will help identify (biomarkers) genetics and inflammatory markers that predict chemotherapy-induced peripheral neuropathy? So the GENIE Study aims to develop biomarkers for peripheral neuropathy in patients treated with taxane chemotherapy for breast cancer patients. Peripheral neuropathy occurs in about 70% of patients with breast cancer. They’re treated with taxanes. Most of those patients will have relatively mild symptoms that resolve shortly after their infusion. But in a subset of patients, those symptoms can be pretty severe. And in some patients, that can also persist…

Biomarkers: Breast Cancer – Daniel Rotroff SABCS 2022 GENIE Trial What will help identify (biomarkers) genetics and inflammatory markers that predict chemotherapy-induced peripheral neuropathy? So the GENIE Study aims to develop biomarkers for peripheral neuropathy in patients treated with taxane chemotherapy for breast cancer patients. Peripheral neuropathy occurs in about 70% of patients with breast cancer. They’re treated with taxanes. Most of those patients will have relatively mild symptoms that resolve shortly after their infusion. But in a subset of patients, those symptoms can be pretty severe. And in some patients, that can also persist for months or even…

iFrame is not supported! Nemtabrutinib: Jennifer Woyach, MD ASH 2022 – BELLWAVE-001 Study By Jennifer Woyach, MD What did the BELLWAVE-01 study on Nemtabrutinib reveal in patients with relapsed refractory CLL and SLL? So we presented follow up from the phase 1/2 BELLWAVE-001 study of nemtabrutinib in patients with relapsed refractory CLL and SLL. So nemtabrutinib is a non-covalent BTK bruton tyrosine kinase inhibitors (BTKis). It was designed to be able to bind BTK outside of the C481 site, which is where the covalent BTK inhibitors bind. So the idea is that this will be an effective agent, even if…

Nemtabrutinib: Jennifer Woyach, MD ASH 2022 – BELLWAVE-001 Study By Jennifer Woyach, MD What did the BELLWAVE-01 study on Nemtabrutinib reveal in patients with relapsed refractory CLL and SLL? So we presented follow up from the phase 1/2 BELLWAVE-001 study of nemtabrutinib in patients with relapsed refractory CLL and SLL. So nemtabrutinib is a non-covalent BTK bruton tyrosine kinase inhibitors (BTKis). It was designed to be able to bind BTK outside of the C481 site, which is where the covalent BTK inhibitors bind. So the idea is that this will be an effective agent, even if patients develop resistance mutations…

iFrame is not supported! Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA Where is the blood cancer treatment for the patient population with AML? There is such a momentum of new data for acute myeloid leukemia (AML blood cancer) here at this congress, and compared with the early days of chronic myelogenous leukemia and multiple myeloma, where such great medical progress was made, within a few years, we (Notable Labs) had the opportunity to present data just here in New Orleans on juvenile myelomonocytic leukemia. It’s a very rare disease. It is…

Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA Where is the blood cancer treatment for the patient population with AML? There is such a momentum of new data for acute myeloid leukemia (AML blood cancer) here at this congress, and compared with the early days of chronic myelogenous leukemia and multiple myeloma, where such great medical progress was made, within a few years, we (Notable Labs) had the opportunity to present data just here in New Orleans on juvenile myelomonocytic leukemia. It’s a very rare disease. It is for collaboration with UCSF’s…

iFrame is not supported! Everolimus: Julie Gralow SABCS 2022 SWOG S1207 in HER2- Breast Cancer What is Everolimus and how can it help patients with HR+ HER2-negative breast cancer? The SWOG S1207 was a trial in the adjuvant breast cancer setting for patients that have hormone receptor positive and HER two negative breast cancer that certain criteria for being at high risk (increased risk) for a distant recurrence. So all patients in this study got endocrine therapy, it could be endocrine therapy of choice, so ovarian function suppression, Tamoxifen, or an aromatase inhibitor and then they were randomized…

Everolimus: Julie Gralow SABCS 2022 SWOG S1207 in HER2- Breast Cancer What is Everolimus and how can it help patients with HR+ HER2-negative breast cancer? The SWOG S1207 was a trial in the adjuvant breast cancer setting for patients that have hormone receptor positive and HER two negative breast cancer that certain criteria for being at high risk (increased risk) for a distant recurrence. So all patients in this study got endocrine therapy, it could be endocrine therapy of choice, so ovarian function suppression, Tamoxifen, or an aromatase inhibitor and then they were randomized to either placebo or…

By Srdan Verstovsek, MD, PhD The VERIFY trial polycythemia vera study examines Rusfertide (PTG-300), a hepcidin mimetic, for patients with polycythemia vera (PV). Presented at ASH 2022 (Poster #1709), this Phase 3 study builds on Phase 2 results. Specifically, it assesses Rusfertide’s ability to reduce phlebotomy needs. So, how does it function, and what could it mean for PV treatment? How Rusfertide Works Rusfertide mimics hepcidin, a key regulator of iron metabolism. Consequently, it restricts iron in the spleen, liver, and GI tract, thus reducing red blood cell production. For PV patients, this decreases phlebotomy, the standard treatment for high…

VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD, PhD How will the VERIFY clinical trial of PTG-300 help patients with polycythemia vera? I’m going to talk about this poster number 1709, which is a presentation of the VERIFY study, a phase 3 study of the Hepcidin Mimetic Rusfertide, also known as PTG-300. In patients with polycythemia vera, this is the study that is underway based on the outcome of the phase 2 open label study with this particular medication. Now, Rusfertide is hepcidin mimetic. What that means is that it is…

RxPONDER trial (SWOG S1007) at SABCS 2022 presented by Yara Abdou, MD from the University of North CarolinaGS1-01 Race and clinical outcomes in the RxPONDER trial (SWOG S1007)Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU,

iFrame is not supported! SV-BR-1-GM: Turning Cells into Antigen-presenting Cells Dr. Williams SABCS 2022 How does SV-BR-1-GM help turn cells into antigen-presenting cells? Now our next presentation was looking at our pipeline development, capitalizing on the observations we’ve. With the Bria-IMT therapy we’ve decided to take our cell line and some other cancer cell lines and to modify them so that they express different HLA types. I mentioned in our monotherapy and in our combination therapy experience with Bria-IMT, that there appears to be a clinical benefit associated with having an HLA match. With the Bria-IMT cell line.…

SV-BR-1-GM: Turning Cells into Antigen-presenting Cells Dr. Williams SABCS 2022 How does SV-BR-1-GM help turn cells into antigen-presenting cells? Now our next presentation was looking at our pipeline development, capitalizing on the observations we’ve. With the Bria-IMT therapy we’ve decided to take our cell line and some other cancer cell lines and to modify them so that they express different HLA types. I mentioned in our monotherapy and in our combination therapy experience with Bria-IMT, that there appears to be a clinical benefit associated with having an HLA match. With the Bria-IMT cell line. So by adding or…

iFrame is not supported! Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and how can it help patients with multiple myeloma? The data that I’m gonna present at the ASH meeting this year is relates to a specific cohort of the KarMMa trial called KarMMa-2 Cohort 2c. And this is a cohort that involves patients who had achieved suboptimal response following autologous stem cell transplantations. These are myeloma patients that have gone through initial induction therapy and stem cell transplantation, but have not achieved a complete remission. And these people were treated with…

Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and how can it help patients with multiple myeloma? The data that I’m gonna present at the ASH meeting this year is relates to a specific cohort of the KarMMa trial called KarMMa-2 Cohort 2c. And this is a cohort that involves patients who had achieved suboptimal response following autologous stem cell transplantations. These are myeloma patients that have gone through initial induction therapy and stem cell transplantation, but have not achieved a complete remission. And these people were treated with a single dose. Of…

iFrame is not supported! Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do for Relapsed/Refractory Multiple Myeloma Patients? ICARIA-MM study was a randomized phase 3 international trial in which we compared Pomalidomide/Dexamethasone to the combination of Isatuximab, Pomalidomide, Dexamethasone and we showed the significant PFS (progression-free survival) benefit. And very importantly at this meeting we presented a survival update, which showed significant survival gains. Now, one of the most important things about the drug is that Isatuximab is obviously similar to Daratumumab and when you have patients in whom Daratumumab was used after…

Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do for Relapsed/Refractory Multiple Myeloma Patients? ICARIA-MM study was a randomized phase 3 international trial in which we compared Pomalidomide/Dexamethasone to the combination of Isatuximab, Pomalidomide, Dexamethasone and we showed the significant PFS (progression-free survival) benefit. And very importantly at this meeting we presented a survival update, which showed significant survival gains. Now, one of the most important things about the drug is that Isatuximab is obviously similar to Daratumumab and when you have patients in whom Daratumumab was used after they had progressed on…

iFrame is not supported! Omentum Based Reconstruction: For Pts with BMI < 25 kg/m Dr. Wapnir SABCS 2022 Will this data analysis or data collection help with patients that receive omentum based reconstruction? One of the benefits that we’re noticing about this procedure is that patients really do not suffer any of the classical morbidities associated with donor sites. Prolonged drainage, large scars, and other deformities seem to have shortened the length of stay in the hospital, and again, there have been no donor sites or symptoms of donor site morbidities for many years. Dr. Nguyen and I recognized…

iFrame is not supported! Tumor-Associated Macrophages: BDC-3042 Animal Model Dr. Kenkel SITC 2022 What are tumor-associated macrophages? Our antibody that we refer to as BDC-3042 targets a molecule known as Dectin-2. This is a potent immune-activating receptor expressed by tumor-associated macrophages, or TAMs, across various types of human solid tumors. Dectin-2 is best known for its role in pathogen recognition and for stimulating immune responses against foreign pathogens. But here we’re actually trying to leverage this expression by TAMs to stimulate an immune response against the cancer rather than against some foreign pathogen. And we are targeting these TAMs using…

Tumor-Associated Macrophages: BDC-3042 Animal Model Dr. Kenkel SITC 2022 What are tumor-associated macrophages? Our antibody that we refer to as BDC-3042 targets a molecule known as Dectin-2. This is a potent immune-activating receptor expressed by tumor-associated macrophages, or TAMs, across various types of human solid tumors. Dectin-2 is best known for its role in pathogen recognition and for stimulating immune responses against foreign pathogens. But here we’re actually trying to leverage this expression by TAMs to stimulate an immune response against the cancer rather than against some foreign pathogen. And we are targeting these TAMs using our antibody, which specifically…

Omentum Based Reconstruction: For Pts with BMI < 25 kg/m Dr. Wapnir SABCS 2022 Will this data analysis or data collection help with patients that receive omentum based reconstruction? One of the benefits that we’re noticing about this procedure is that patients really do not suffer any of the classical morbidities associated with donor sites. Prolonged drainage, large scars, and other deformities seem to have shortened the length of stay in the hospital, and again, there have been no donor sites or symptoms of donor site morbidities for many years. Dr. Nguyen and I recognized that there was an…

iFrame is not supported! How will the decreases in circulating tumor associated cells help patients with metastatic breast cancer? The Other clinical trial looked at circulating tumor associated cells to look at progression-free survival, overall survival. In our pooled analysis of all of our Bria-IMT trials to date where we had done these analyses, we’ve been collaborating with Creative Microtech, Dan Adams is the first author on this poster, and they have developed a very interesting biomark called Cancer Associated Macrophage Like Cells, abbreviated CAMLs, and I’m sure many of you are familiar with circulating tumor cells as a biomarker…

SV-BR-1-GM: Pooled Analysis Predicts PFS and OS Dr. Williams SABCS 2022 How will the decreases in circulating tumor associated cells help patients with metastatic breast cancer? The Other clinical trial looked at circulating tumor associated cells to look at progression-free survival, overall survival. In our pooled analysis of all of our Bria-IMT trials to date where we had done these analyses, we’ve been collaborating with Creative Microtech, Dan Adams is the first author on this poster, and they have developed a very interesting biomark called Cancer Associated Macrophage Like Cells, abbreviated CAMLs, and I’m sure many of you are…

iFrame is not supported! Car- T DDBMCA By Matthew Frigault, MD Car T cell DDBMCA is a autologous chimeric enogen receptor T-cell. So it’s a type of an immunogen therapy that targets BCMA, which is antigen on multiple myeloma. It is a first.Study until this hasn’t been used in other patients for other reasons or other indications. There are other BCMA car T-cell therapy but this is built differently to hopefully be more effective. And it is a phase 1 dose escalation first in human study.So this was we looked at patients who were defined as relapse refractory. So it…

iFrame is not supported! Axi-cel: Zuma 7 was a randomized phase three study By Armin Ghobadi, MD Zuma 7 was a randomized phase three study that used Axi-Cel versus a standard of. Care chemotherapy followed by autologous transplant.In a second line setting for most patients with relapsed refractory large B-cell lymphoma. That means adult patient with relapse refractory large B-cell lymphoma being refractory to the first line therapy or relapse within the first 12 months of therapy, they’re randomized to access lc, the 19 car versus the standard of care that was chemo followed by. Axi-Cel outcome was superior to…

iFrame is not supported! Car- T DDBMCA By Matthew Frigault, MD Car T cell DDBMCA is a autologous chimeric enogen receptor T-cell. So it’s a type of an immunogen therapy that targets BCMA, which is antigen on multiple myeloma. It is a first.Study until this hasn’t been used in other patients for other reasons or other indications. There are other BCMA car T-cell therapy but this is built differently to hopefully be more effective. And it is a phase 1 dose escalation first in human study.So this was we looked at patients who were defined as relapse refractory. So it…

Axi-cel: Zuma 7 was a randomized phase 3 study By Armin Ghobadi, MD Zuma 7 was a randomized phase three study that used Axi-Cel versus a standard of. Care chemotherapy followed by autologous transplant.In a second line setting for most patients with relapsed refractory large B-cell lymphoma. That means adult patient with relapse refractory large B-cell lymphoma being refractory to the first line therapy or relapse within the first 12 months of therapy, they’re randomized to access lc, the 19 car versus the standard of care that was chemo followed by. Axi-Cel outcome was superior to a standard of care,…

iFrame is not supported! Efgartigimod By Catherine Broome, MD We presented data on Efgartigimod in a phase three trial called Advanced iv, which looked at Efgartigimod compared to placebo in a randomized controlled trial in patients with chronic ITP 18 years of age or. Efgartigimod or placebo intravenously over a 24 week trial All patients had failed at least one prior line of I t P therapy and were either on concurrent therapy that was not effective or had failed more than two lines of therapy. They were randomized two to one to receive Efgartigimod or placebo intravenously over a…

Efgartigimod By Catherine Broome, MD We presented data on Efgartigimod in a phase three trial called Advanced iv, which looked at Efgartigimod compared to placebo in a randomized controlled trial in patients with chronic ITP 18 years of age or. Efgartigimod or placebo intravenously over a 24 week trial All patients had failed at least one prior line of I t P therapy and were either on concurrent therapy that was not effective or had failed more than two lines of therapy. They were randomized two to one to receive Efgartigimod or placebo intravenously over a 24 week trial. And…

LW-02 Cartridge: Immunicom Therapy Amir Jafri CEO and Founder What is the LW-02 Cartridge Therapy? Immunicom was actually formed in 2013. It actually was the byproduct of my wife who’s a physician here in San Diego. And not only her experiences with her patients but also personal experiences that she had, people that she knew in the community, friends of hers. That really drove her to, looking for a solution and particularly for cancer patients. That wasn’t toxic, that wasn’t gonna destroy the patient’s lives. And there was actually a friend of hers, she was a single mother…

iFrame is not supported! SV-BR-1-GM: Whole Cell Therapeutic Vaccine Dr. Williams SABCS 2022 What is SV-BR-1-GM Whole Cell Therapeutic Vaccine and how can it help patients with metastatic breast cancer? I want to introduce you to BriaCell and to our therapeutic approach. I’m gonna start by sharing my screen and show you, the way our therapy works. We’ve developed a cellular approach to cancer immunotherapy, that’s also a targeted approach. The way that it works is that we’ve isolated a breast cancer cell line. Which we call Bria-IMT, and this breast cancer cell line has multiple functions. It’s been…

SV-BR-1-GM: Whole Cell Therapeutic Vaccine Dr. Williams SABCS 2022 What is SV-BR-1-GM Whole Cell Therapeutic Vaccine and how can it help patients with metastatic breast cancer? I want to introduce you to BriaCell and to our therapeutic approach. I’m gonna start by sharing my screen and show you, the way our therapy works. We’ve developed a cellular approach to cancer immunotherapy, that’s also a targeted approach. The way that it works is that we’ve isolated a breast cancer cell line. Which we call Bria-IMT, and this breast cancer cell line has multiple functions. It’s been stably transected with the…

Inherited Thrombophilia: Pregnancy & Heparin – Middeldorp, MD- ASH 2022 By Saskia Middeldorp, MD I’m able to present the results of the ALIFE2 trial for you today. For everyone tomorrow. This trial investigated low molecular weight heparin and standard pregnancy care.First, a standard pregnancy care alone for women with recurrent miscarriage and inherited forms of Thrombophilia. , we have previously shown that in unexplained recurrent miscarriage antithrombotic therapy with low molecular heparin or aspirin does not help. in women with Thrombophilia in that trial, however, we noticed a relative risk of 31.31, so 30% more chances of having a live…

Zanubrutinib: Superior PFS in CLL Jennifer Brown, MD – ASH 2022 By Jennifer Brown, MD I’ll be discussing the alpine study today. By way of background, we note that Bruton tyrosine kinase inhibition and CLL has been transformative. Of its therapy because B-cell receptor signaling is required for tumor expansion and proliferation in CLL and B-cell lymphomas, and that B-cell receptor signaling is dependent on btk.Ibrutinib is the first in class covalent BTK inhibitor. Which did transform CLL therapy, but has properties that limit its use, particularly treatment discontinuation from toxicities with discontinuing rates of 16 to 23% across many…

Blinatumomab: ECOG-ACRIN E1910 National Clinical Trials Network Clinical trial By Mark Litzow, MD ECOG-ACRIN E1910 National Clinical Trials Network Clinical trial. This is a phase three randomized trial. Blinatumomab for newly diagnosed bcr A negative. We also refer to the bcr. Gene Rearrangement is a Philadelphia chromosome. So these patients were negative for this finding, but they had acute lymphoblastic leukemia. Acute lymphoblastic leukemias is the acute leukemia counterpart of what Dr.Brown just told you about chronic lymphocytic leukemia. And these are the detectable cancer cells that we worry about. These are the blast cells that don’t function. And cause…

iFrame is not supported! Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the study of Pacritinib in the PACIFICA Clinical Trial in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis? The study we’re talking about is the PACIFICA study, which is a phase 3 randomized study of Pacritinib. The JAK2/IRAK1/ACVR1, ACVR1 inhibitor. Compared to best available therapy in patients who have platelet counts, myelofibrosis, patients who have platelet counts less than 50,000. And this is a clinical trial post-marketing, so the drug is now approved in the US with…

Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the study of Pacritinib in the PACIFICA Clinical Trial in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis? The study we’re talking about is the PACIFICA study, which is a phase 3 randomized study of Pacritinib. The JAK2/IRAK1/ACVR1, ACVR1 inhibitor. Compared to best available therapy in patients who have platelet counts, myelofibrosis, patients who have platelet counts less than 50,000. And this is a clinical trial post-marketing, so the drug is now approved in the US with a label for patients…

iFrame is not supported! Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD What is the DASCERN clinical trial that treated patients chronic phase chronic myeloid leukemia?  The Dasatinib is a tyrosine kinase inhibitor where we refer to as a second generation tyrosine kinase inhibitors. It’s a very potent inhibitor of B or able but it is also inhibits other kinases. It inhibits, CT PGA receptor it also inhibits SARC and it is more potent than Imatinib treatment. For example, the first generation TKI, and it was actually initially developed as the as…

Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD What is the DASCERN clinical trial that treated patients chronic phase chronic myeloid leukemia?  The Dasatinib is a tyrosine kinase inhibitor where we refer to as a second generation tyrosine kinase inhibitors. It’s a very potent inhibitor of B or able but it is also inhibits other kinases. It inhibits, CT PGA receptor it also inhibits SARC and it is more potent than Imatinib treatment. For example, the first generation TKI, and it was actually initially developed as the as a treatment for patients…

iFrame is not supported! Momelotinib: Update On MOMENTUM Trial Dr. Gerds ASH 2022 By Aaron Gerds, MD What is the difference between the Momelotinib arm and the Danazol arm of the trial? It’s a great question, and Momelotinib has been around for a while. It is a JAK inhibitor primarily and was tested in two large randomized phase 3 trials. The SIMPLIFY-1 and 2, and both of those studies did not reach their primary endpoints, largely due to poor trial design. And ultimately, when the compound changed hands, it was sold to a couple of different companies, and now it…

Momelotinib: Update On MOMENTUM Trial Dr. Gerds ASH 2022 By Aaron Gerds, MD What is the difference between the Momelotinib arm and the Danazol arm of the trial? It’s a great question, and Momelotinib has been around for a while. It is a JAK inhibitor primarily and was tested in two large randomized phase 3 trials. The SIMPLIFY-1 and 2, and both of those studies did not reach their primary endpoints, largely due to poor trial design. And ultimately, when the compound changed hands, it was sold to a couple of different companies, and now it is resurrected. And…

iFrame is not supported! Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan Oluwole, MD, MPH, MBBS What is the ZUMA-1 Cohort 6 clinical trials in large b-cell lymphoma (R/R LBCL)? So my study is title Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel), Axicabtagene Ciloleucel (Axi-Cel) also called Axu-Cell. It is FDA approved for the treatment of light cell lymphoma, and there are patients that develop cytokine release syndrome and neurological toxicity. And the question was whether this treatment that has been so effective can also be given in a safer way. In…

iFrame is not supported! Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD How can Mezigdomide (CC-92480) help patients with multiple myeloma? The important point is that Mezigdomide (CC-92480) is an oral therapy that is a, what we call a new class of drugs called cell mods. These are highly potent small molecules which work by targeting the degradation of Ikaros and Aiolos, which are key transcription factors for multiple myeloma pathobiology. They’re also very important in lymphoma as well, actually. But in myeloma, they’re a key target. These the engagement or…

Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan Oluwole, MD, MPH, MBBS What is the ZUMA-1 Cohort 6 clinical trials in large b-cell lymphoma (R/R LBCL)? So my study is title Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel), Axicabtagene Ciloleucel (Axi-Cel) also called Axu-Cell. It is FDA approved for the treatment of light cell lymphoma, and there are patients that develop cytokine release syndrome and neurological toxicity. And the question was whether this treatment that has been so effective can also be given in a safer way. In other words, maybe if…

Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD How can Mezigdomide (CC-92480) help patients with multiple myeloma? The important point is that Mezigdomide (CC-92480) is an oral therapy that is a, what we call a new class of drugs called cell mods. These are highly potent small molecules which work by targeting the degradation of Ikaros and Aiolos, which are key transcription factors for multiple myeloma pathobiology. They’re also very important in lymphoma as well, actually. But in myeloma, they’re a key target. These the engagement or the degradation of these…

iFrame is not supported! Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the Connect® MM Registry and how did COVID-19 impact multiple myeloma Patients? So this is a very interesting study in that it utilizes the Connect Multiple Myeloma Registry (Connect® MM Registry). The registry was established in 2009, and it’s one of the oldest and largest myeloma registries. We recruited (multiple myeloma) patients in 2 cohorts, 1500 (multiple myeloma patients) for the first cohort, followed by another cohort of 1500 (multiple myeloma patients). And what was unique about our registry is over…

Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the Connect® MM Registry and how did COVID-19 impact multiple myeloma Patients? So this is a very interesting study in that it utilizes the Connect Multiple Myeloma Registry (Connect® MM Registry). The registry was established in 2009, and it’s one of the oldest and largest myeloma registries. We recruited (multiple myeloma) patients in 2 cohorts, 1500 (multiple myeloma patients) for the first cohort, followed by another cohort of 1500 (multiple myeloma patients). And what was unique about our registry is over time we’re able to…

iFrame is not supported! Clonal Hematopoiesis: Myeloid Malignancy Prediction – ASH 2022 By LaChelle Weeks, MD, PhD What is clonal hematopoiesis and why is it a clinical significance? Going back to around 2014, folks in our lab fully characterized clonal hematopoiesis of indeterminate potential, or CHIP. And this is a precursor to cancers like leukemia or classic syndromes—blood cancers that are very hard to treat once they’re identified. And so this really opened up a new potential for early interception and early prevention in acute leukemias, which is something we haven’t had before. We have this in the solid malignancies,…

Clonal Hematopoiesis: Myeloid Malignancy Prediction – ASH 2022 By LaChelle Weeks, MD, PhD What is clonal hematopoiesis and why is it a clinical significance? Going back to around 2014, folks in our lab fully characterized clonal hematopoiesis of indeterminate potential, or CHIP. And this is a precursor to cancers like leukemia or classic syndromes—blood cancers that are very hard to treat once they’re identified. And so this really opened up a new potential for early interception and early prevention in acute leukemias, which is something we haven’t had before. We have this in the solid malignancies, of course, with early…

iFrame is not supported! Tamoxifen: TAM-01 Long Term Follow-up with Andrea De Censi SABCS 2022 What is TAM-01 long term follow-up data? Tamoxifen is a selective estrogen receptor modulator (SERMs). Which has been used firstly in the metastatic setting in women with advanced breast cancer, and then moved to the adjuvant setting where it show a survival advantage in estrogen receptor positive disease. The dose that was selected is 20 milligrams every day. And it is associated; it is a well tolerated drug, but has some serious adverse events, namely endometrial cancer, venous thromboembolic events, and most importantly, in…

Tamoxifen: TAM-01 Long Term Follow-up with Andrea De Censi SABCS 2022 What is TAM-01 long term follow-up data? Tamoxifen is a selective estrogen receptor modulator (SERMs). Which has been used firstly in the metastatic setting in women with advanced breast cancer, and then moved to the adjuvant setting where it show a survival advantage in estrogen receptor positive disease. The dose that was selected is 20 milligrams every day. And it is associated; it is a well tolerated drug, but has some serious adverse events, namely endometrial cancer, venous thromboembolic events, and most importantly, in the provincial setting, menopausal…

iFrame is not supported! Capivasertib: CAPItello-291 Results with Slides Nicholas Turner SABCS 2022 Presentation from the SABCS 2022 (San Antonia Breast Cancer Symposium) Thank you very much. Carlos. So it’s a pleasure to present the prime results of CAPItello-291 phase III study on behalf of my co-authors. Akt activation is very frequent in hormone receptor positive HER2-negative advanced breast cancer through genetic alterations in the pathway, but also make a current cancers without genetic alterations. AKT signaling is also implicated in the clinical development of endocrine (therapy) resistance. So Capivasertib was developed as a potent and selective inhibitor of…

iFrame is not supported! Elacestrant PFS Increase ER+ HER2- Dr. Kaklamani, MD SABCS 2022 What is the EMERALD Trial In ER-positive, HER2-negative Metastatic Breast Cancer Patients? The EMERALD trial is a phase 3 clinical trial in women with ER-positive, HER2-negative metastatic breast cancer, were randomized after receiving and progressing on a CDK4/6 inhibitor to receive either Elacestrant, which is an oral SERT, or standard of care endocrine therapy, which was either Fulvestrant or an aromatase inhibitor depending on what endocrine therapy they had received previously. There were two primary endpoints for the trial. The first one was progression-free…

Elacestrant PFS Increase ER+ HER2- Dr. Kaklamani, MD SABCS 2022 What is the EMERALD Trial In ER-positive, HER2-negative Metastatic Breast Cancer Patients? The EMERALD trial is a phase 3 clinical trial in women with ER-positive, HER2-negative metastatic breast cancer, were randomized after receiving and progressing on a CDK4/6 inhibitor to receive either Elacestrant, which is an oral SERT, or standard of care endocrine therapy, which was either Fulvestrant or an aromatase inhibitor depending on what endocrine therapy they had received previously. There were two primary endpoints for the trial. The first one was progression-free survival, and the second…

iFrame is not supported! MUC4 Nude Mouse Model Trail in HER2+ Breast Cancer INmune Bio is focused on the innate immune system in many diseases, and our interests that we’re talking about today relate to cancer and the immunology of the tumor microenvironment. And it turns out it’s important because, It’s breast cancer, and in fact, it’s HER2+ breast cancer. HER2+ breast cancer is now with the modern therapies, half of all cancers. It is an aggressive form of cancer and there’s a lot of great solutions for these women with breast cancer, but they still relapse. And why…

iFrame is not supported! Camizestrant: Results of the Randomized Phase 2 SERENA-2 Trial (with slides) Thank you, Carlos. Thank you, everyone, for the opportunity to be here and present the firsthand results of the tool trial. So these are my disclosures. Camizestrant is a oral selective ER, degrader, and antagonist that has been tested in a phase 1 study, across a range of doses and has shown a very good profile of inhibition of the ER, and we designed SERENA-2 to assess different doses of Camizestrant in comparison with the standard of care with Fulvestrant in patients progressing to…

iFrame is not supported! Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O’Reagan What is the Breast Cancer Index? Ruth Regan, who is a professor and chair of the Department of Medicine at the University of Rochester. And her presentation is evaluation of the breast cancer index in premenopausal women with early stage HR+ breast cancer in the soft trial. Thank you, Virginia. Good afternoon, everybody, and thank you for staying for this. What is the Breast Cancer Index (BCI)? So I’m happy to present the (BCI test) results of the analysis of Breast Cancer Index in premenopausal women…

Capivasertib: CAPItello-291 Results with Slides Nicholas Turner SABCS 2022 Presentation from the SABCS 2022 (San Antonia Breast Cancer Symposium) Thank you very much. Carlos. So it’s a pleasure to present the prime results of CAPItello-291 phase III study on behalf of my co-authors. Akt activation is very frequent in hormone receptor positive HER2-negative advanced breast cancer through genetic alterations in the pathway, but also make a current cancers without genetic alterations. AKT signaling is also implicated in the clinical development of endocrine (therapy) resistance. So Capivasertib was developed as a potent and selective inhibitor of all 3 Akt isoforms.…

Francois-Clement Bidard, MD, PhD of Institut Curiediscusses Circulating tumor cells enumeration and Health Related Quality of Life of patients treated with first-line chemotherapy for HER2 negative metastatic breast cancer

MUC4 Nude Mouse Model Trail in HER2+ Breast Cancer INmune Bio is focused on the innate immune system in many diseases, and our interests that we’re talking about today relate to cancer and the immunology of the tumor microenvironment. And it turns out it’s important because, It’s breast cancer, and in fact, it’s HER2+ breast cancer. HER2+ breast cancer is now with the modern therapies, half of all cancers. It is an aggressive form of cancer and there’s a lot of great solutions for these women with breast cancer, but they still relapse. And why am I saying HER2+…

Camizestrant: Results of the Randomized Phase 2 SERENA-2 Trial (with slides) Thank you, Carlos. Thank you, everyone, for the opportunity to be here and present the firsthand results of the tool trial. So these are my disclosures. Camizestrant is a oral selective ER, degrader, and antagonist that has been tested in a phase 1 study, across a range of doses and has shown a very good profile of inhibition of the ER, and we designed SERENA-2 to assess different doses of Camizestrant in comparison with the standard of care with Fulvestrant in patients progressing to prior endocrine therapy. So…

Yen-Shen Lu, MD of National Taiwan University discusses Ribociclib and the Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy

RxPONDER trial (SWOG S1007) at SABCS 2022 presented by Yara Abdou, MD from the University of North CarolinaGS1-01 Race and clinical outcomes in the RxPONDER trial (SWOG S1007)Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU,

Getting description

Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O’Reagan What is the Breast Cancer Index? Ruth Regan, who is a professor and chair of the Department of Medicine at the University of Rochester. And her presentation is evaluation of the breast cancer index in premenopausal women with early stage HR+ breast cancer in the soft trial. Thank you, Virginia. Good afternoon, everybody, and thank you for staying for this. What is the Breast Cancer Index (BCI)? So I’m happy to present the (BCI test) results of the analysis of Breast Cancer Index in premenopausal women who enrolled in the…

HER2-Low: Anastrozole TRIO-US B-12 TALENT SABCS 2022Aditya Bardia, MD of Mass General discusses theGS2-03: TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

Trastuzumab emtansine versus Trastuzumab deruxtecan versus in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03Sara A. Hurvitz, MD, UCLA Health discusses the released data for Phase 3 study entitled DESTINY-Breast03 at SABCS 2022

Trastuzumab deruxtecan DESTINY-Breast02 results presented at SABCS 2022 with Ian E. Krop, MD, PhD Yale School of Medicine.GS2-01: Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02 With Slides

SABCS 2022 Day 2 Press Conference December 7, 2022. Ian E. Krop, MD, PhD from Yale University discusses Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02Sara Hurvitz, MD from UCLA Health discusses Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03Aditya Bardia, MD, MPH from Massachusetts General Hospital discusses TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

iFrame is not supported! Ribociclib: SABCS 2022 Phase II RIGHT Choice Trial in Breast Cancer What is the RIGHT Choice ribociclib clinical trial as opposed to current clinical practice standards? So for aggressive disease status, conventionally, doctors (healthcare professional) will try to prescribe chemotherapy instead of initial endocrine therapy based regimen. So for postmenopausal patients, single aging chemotherapy is preferred, But for premenopausal patients, doctors will consider that some of them have a more aggressive tumor biology, so the tumor may grow faster. Secondly, the patient may be more tolerant of the side effects of combination chemotherapy. So that…

Ribociclib: SABCS 2022 Phase II RIGHT Choice Trial in Breast Cancer What is the RIGHT Choice ribociclib clinical trial as opposed to current clinical practice standards? So for aggressive disease status, conventionally, doctors (healthcare professional) will try to prescribe chemotherapy instead of initial endocrine therapy based regimen. So for postmenopausal patients, single aging chemotherapy is preferred, But for premenopausal patients, doctors will consider that some of them have a more aggressive tumor biology, so the tumor may grow faster. Secondly, the patient may be more tolerant of the side effects of combination chemotherapy. So that is why combination chemotherapy…

iFrame is not supported! VAL-083: Dennis Brown [2022]: Key Facts To Consider Glioblastoma VAL-083, or it’s chemical name dianhydrogalactitol (val-083), is a compound that came through the National Cancer Institute (NIC), which runs massive screens around the world looking for new cancer agents. And the NCI (National Cancer Institute) still performs those duties, even though there’s a large network of smaller and larger corporations now focused on oncology. So VAL-083 is a small molecule. And it’s unique in the sense that it’s a sugar that’s derived with reactive epoxide groups. And this small molecule has the ability to…

VAL-083: Dennis Brown [2022]: Key Facts To Consider Glioblastoma VAL-083, or it’s chemical name dianhydrogalactitol (val-083), is a compound that came through the National Cancer Institute (NIC), which runs massive screens around the world looking for new cancer agents. And the NCI (National Cancer Institute) still performs those duties, even though there’s a large network of smaller and larger corporations now focused on oncology. So VAL-083 is a small molecule. And it’s unique in the sense that it’s a sugar that’s derived with reactive epoxide groups. And this small molecule has the ability to cross the blood brain…

iFrame is not supported! Omidubicel: Ronit Simantov Phase 3 Results [2022] Blood Cancers What is omidubicel and can this improve clinical outcomes? – Omidubicel is was developed as a stem cell source for use in patients who need an allogeneic stem cell transplant(stem cell transplantation). And these are patients with hematological malignancies like leukemia, myelodysplastic syndrome, lymphoma, and other diseases. Patients receiving omidubicel is derived from umbilical cord blood, which was identified years ago as a source of hematopoietic stem cells. But because of the size of (umbilical) cord blood, it often contains too few cells to serve…

Omidubicel: Ronit Simantov Phase 3 Results [2022] Blood Cancers What is omidubicel and can this improve clinical outcomes? – Omidubicel is was developed as a stem cell source for use in patients who need an allogeneic stem cell transplant(stem cell transplantation). And these are patients with hematological malignancies like leukemia, myelodysplastic syndrome, lymphoma, and other diseases. Patients receiving omidubicel is derived from umbilical cord blood, which was identified years ago as a source of hematopoietic stem cells. But because of the size of (umbilical) cord blood, it often contains too few cells to serve as an effective transplant…

iFrame is not supported! Codagenix: What is CodaLytic? Who’s the target? Could Oncolytic Viruses Be Dangerous? CodaLytic is a novel Oncolytic virus that Codagenix, Inc is developing in the context of breast cancer. Oncolytic viruses in general are a relatively novel modality. These are live viruses (or live vaccines) engineered in a way that they can specifically infect and replicate, and cancer cells destroy some of these cancer cells and then trigger an anti-tumor immune response that ultimately alert the immune system to the cancer, fights it, and induces responses that can hopefully lead to durable responses in patients…

Codagenix: What is CodaLytic? Who’s the target? Could Oncolytic Viruses Be Dangerous? CodaLytic is a novel Oncolytic virus that Codagenix, Inc is developing in the context of breast cancer. Oncolytic viruses in general are a relatively novel modality. These are live viruses (or live vaccines) engineered in a way that they can specifically infect and replicate, and cancer cells destroy some of these cancer cells and then trigger an anti-tumor immune response that ultimately alert the immune system to the cancer, fights it, and induces responses that can hopefully lead to durable responses in patients and transform their lives.…

iFrame is not supported! LCMC3 Neoadjuvant Atezolizumab Phase 2 Study Results What is the LCMC3 (Lung Cancer Mutation Consortium) Trial? So, this is a consortium of academic institutions across the United States that collaborate with each other to conduct molecularly based clinical trials to advance the state of the art of lung cancer (neoadjuvant) therapy. What Is The Current Standard Of Care For Patients With Lung Cancer? The current standard of care for lung cancer has become very complex in clinical oncology, and I can’t review every aspect of it, but basically, there are two types of non-small…

LCMC3 Neoadjuvant Atezolizumab Phase 2 Study Results What is the LCMC3 (Lung Cancer Mutation Consortium) Trial? So, this is a consortium of academic institutions across the United States that collaborate with each other to conduct molecularly based clinical trials to advance the state of the art of lung cancer (neoadjuvant) therapy. What Is The Current Standard Of Care For Patients With Lung Cancer? The current standard of care for lung cancer has become very complex in clinical oncology, and I can’t review every aspect of it, but basically, there are two types of non-small cell lung cancer (NSCLC)…

iFrame is not supported! Lisocabtagene Maraleucel has been approved by the FDA for the second-line treatment of large B cell lymphoma LBCL Lisocabtagene Maraleucel Key Statistics: 65% risk reduction of event-free survival in the Lisocabtagene Maraleucel arm. 10.1 months (95% confidence interval: 6.1, not evaluable) estimated median event-free survival compared to 2.3 months (95% confidence interval: 2.2, 4.3). 59% risk reduction in progression-free survival in the Lisocabtagene Maraleucel arm compared to standard of care. Lisocabtagene Maraleucel is not approved to treat people with primary central nervous system lymphoma. Hazard ratio (HR) of 0.34 (95% CI:0.22, 0.52; p-value0.0001), event-free survival was…

iFrame is not supported! Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial 5 Key Conclusions: VS-6766 as a potential backbone of therapy for RAS pathway-driven cancers VS-6766 is a dual RAF/MEK with anti-tumor activity across multiple MAPK pathway alterations and multiple solid tumor indications VS-6766 + defactinib (FAKi) has shown 46% ORR (11/24) [64% ORR (7/11) in KRAS mt] with 23 months mPFS in LGSOC o Registration-directed clinical trial in progress (RAMP-201; NCT04625270) VS-6766 ± defactinib (FAKi) has shown 57% ORR (4/7) in KRAS G12V mt NSCLC o Registration-directed clinical trial…

iFrame is not supported! Is Interstitial Lung Disease a Manageable Adverse Event of Trastuzumab T-DXd Deruxtecan Treatment? What is Trastuzumab T-DXd? Trastuzumab T-DXd is an antibody-drug conjugate that consists of an antibody that binds to the HER-2 receptor that can be over-expressed or mutated in several different cancers. That is covalently linked to a payload. In this case, it’s a topoisomerase one inhibitor, a very potent chemotherapeutic drug, which has high toxicity typically when administered systemically. So there are advantages to the antibody-drug conjugate approach so that the payload is delivered preferentially to cells that express the HER-2 receptor. When…

iFrame is not supported! Biomarkers RNA: [2022] What Is ASPYRE Technology? How Can This Help Patients With Non-small Cell Lung Cancer (NSCLC)? I would like to speak with you today and tell you a little bit about ASPYRE and Biofidelity. So Biofidelity recently published a paper in BMC Medical Genomics describing a new technology called ASPYRE, and this really summarizes the low cost. A simple, very rapid assay for multi-molecule detection of multiple gene fusions from RNA. And the paper describes the assay for how detecting these fusions faster and at a lower cost has the potential to…

iFrame is not supported! KRAS G12C Sotorasib: [2022] An Updated Overview in CRC Update On The CodeBreaK 100 Trial/KRAS G12C Sotorasib The CodeBreaK 100 is a very large clinical trial that started with a safety study, phase 1, to define the recommended dose of Sotorasib (AMG 510) in patients with KRAS G12C-Mutations. This study was open for patients with non-small cell lung cancer (NSCLC), patients with colorectal cancer and all solid tumors with KRAS G12C-Mutation. The study initially defined that the 9/60 milligram dose of Sotorasib (AMG 510) once daily is the recommended dose to go further. It…

iFrame is not supported! IDE196 Solid Tumors GNAQ/11 Mutations or PRKC Fusions [2022] What is IDE196? And How Will It Help Patients With Solid Tumors? Recently, there have been phase 2 clinical data announcements regarding a subset of patients treated in the study. So there were 37 patients treated in a cohort of patients with DVA 300 milligrams twice daily and crizotinib 200 milligrams twice daily. So there were 35 invaluable patients, and excitingly, 89% of patients did have a decrease in their tumor, and the response rate was 50%. In order for half of the patients to achieve a…

iFrame is not supported! MIRAGE Trial Phase 3: CT / MRI SBRT Which is Better? [2022] Which is Better: CT or MRI SBRT in Prostate Cancer? So traditionally, radiation therapy, when it’s delivered in an external beam format, has relied on x-ray or CT-based imaging. MRI imaging provides very good space, full contrast, and resolution for certain targets, for example, targets in the pelvis such as the prostate. But historically, it has been technically difficult to integrate an MRI with a linear accelerator, which is what delivers the dose. High-energy x-rays and external beam radiotherapy There are two commercially…

Biomarkers RNA: [2022] What Is ASPYRE Technology? How Can This Help Patients With Non-small Cell Lung Cancer (NSCLC)? I would like to speak with you today and tell you a little bit about ASPYRE and Biofidelity. So Biofidelity recently published a paper in BMC Medical Genomics describing a new technology called ASPYRE, and this really summarizes the low cost. A simple, very rapid assay for multi-molecule detection of multiple gene fusions from RNA. And the paper describes the assay for how detecting these fusions faster and at a lower cost has the potential to really revolutionize patient care…

KRAS G12C Sotorasib: [2022] An Updated Overview in CRC Update On The CodeBreaK 100 Trial/KRAS G12C Sotorasib The CodeBreaK 100 is a very large clinical trial that started with a safety study, phase 1, to define the recommended dose of Sotorasib (AMG 510) in patients with KRAS G12C-Mutations. This study was open for patients with non-small cell lung cancer (NSCLC), patients with colorectal cancer and all solid tumors with KRAS G12C-Mutation. The study initially defined that the 9/60 milligram dose of Sotorasib (AMG 510) once daily is the recommended dose to go further. It was quite well tolerated…

IDE196 Solid Tumors GNAQ/11 Mutations or PRKC Fusions [2022] What is IDE196? And How Will It Help Patients With Solid Tumors? Recently, there have been phase 2 clinical data announcements regarding a subset of patients treated in the study. So there were 37 patients treated in a cohort of patients with DVA 300 milligrams twice daily and crizotinib 200 milligrams twice daily. So there were 35 invaluable patients, and excitingly, 89% of patients did have a decrease in their tumor, and the response rate was 50%. In order for half of the patients to achieve a partial response of greater…

MIRAGE Trial Phase 3: CT / MRI SBRT Which is Better? [2022] Which is Better: CT or MRI SBRT in Prostate Cancer? So traditionally, radiation therapy, when it’s delivered in an external beam format, has relied on x-ray or CT-based imaging. MRI imaging provides very good space, full contrast, and resolution for certain targets, for example, targets in the pelvis such as the prostate. But historically, it has been technically difficult to integrate an MRI with a linear accelerator, which is what delivers the dose. High-energy x-rays and external beam radiotherapy There are two commercially available MRI-guided linear accelerators…

7-gene DCIS Assay [2022] Comparing Clinicopathologic Features 7-gene DCIS Assay: For several decades in clinical oncology, when it comes to DCIS, or (invasive) ductal carcinoma insights, for several decades, we’ve recommended all women (diagnosed with Breast Cancer) who undergo lumpectomy receive radiation based on a 50% reduction in recurrence in the breast (cancer). We’ve tried to identify (DCIS) patients that don’t benefit from (adjuvant) radiation therapy, but using traditional clinical factors as well as pathologic factors has failed to identify a subset of residual risk patients that don’t benefit from radiation therapy with respect to local. The decision RT…

iFrame is not supported! Lung SBRT Dose Optimization [2022]: Overcoming Size & SUV? When Was Lung SBRT (stereotactic body radiation therapy) Treatment Developed? Lung SBRT (treatment) started in the late, 1990s, early 2000s. It was initially adapted in Japan, when radiation technology (using radiation beams) became, sophisticated enough to, instead of having one or two or three beams, coming from just a couple of directions aimed by an x-ray with a big giant rectangular target in the. As soon as the technology adapted the CT planning and controlling for tumor motion and allowing many beam angles so that you…

7-gene DCIS Assay [2022] Comparing Clinicopathologic Features 7-gene DCIS Assay: For several decades in clinical oncology, when it comes to DCIS, or (invasive) ductal carcinoma insights, for several decades, we’ve recommended all women (diagnosed with Breast Cancer) who undergo lumpectomy receive radiation based on a 50% reduction in recurrence in the breast (cancer). We’ve tried to identify (DCIS) patients that don’t benefit from (adjuvant) radiation therapy, but using traditional clinical factors as well as pathologic factors has failed to identify a subset of residual risk patients that don’t benefit from radiation therapy with respect to local. The decision RT…

Lung SBRT Dose Optimization [2022]: Overcoming Size & SUV? When Was Lung SBRT (stereotactic body radiation therapy) Treatment Developed? Lung SBRT (treatment) started in the late, 1990s, early 2000s. It was initially adapted in Japan, when radiation technology (using radiation beams) became, sophisticated enough to, instead of having one or two or three beams, coming from just a couple of directions aimed by an x-ray with a big giant rectangular target in the. As soon as the technology adapted the CT planning and controlling for tumor motion and allowing many beam angles so that you could shape the size…

iFrame is not supported! Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician’s Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2 Clinical Trial) By Naval Daver, MD The study we are conducting here is a randomized phase 3 international study of Azacitidine Magrolimab (Hu5F9-G4), versus investigator choice therapy of either Azacitidine Venetoclax or intensive three plus seven, specifically in a molecular subset of TP53-mutated (TP53m), acute myeloid leukemia. The goal of this study is to see whether the combination treatment of…

iFrame is not supported! NRG / RTOG 1112 Phase 3 Trial: ASTRO [2022] Nrg/RTOG 1112 A Randomized Phase III Study The NRG/RTOG 1112 (NRG Oncology RTOG 112) clinical trial focuses on patients with hepatocellular carcinoma, a group of patients who are understudied and in need of better treatments. At the start of this study, sorafenib was the standard of care for patients treated with locally advanced hepatocellular carcinoma that could not be removed and did not respond well to standard local ablation therapies or hepatic arterial regional therapies like TACE. And so that is why sorafenib is the backbone systemic…

iFrame is not supported! Cribriform CAP Intraductal Carcinoma Prostate [2022] Cribriform Prostate Cancer Clinical Trial I’m here to talk about our recent study, presented at ASTRO’s annual meeting. In this study, the gene expression or transcriptome characteristics of aggressive prostate cancer were looked at and found to be linked. morphologic appearance under the microscope as characterized by our genitor urinary pathologists, who are primary co-authors on the study. In particular, they were looking at this aggressive morphology or morphology associated with aggressive clinical behavior called cribriform or intraductal cancer of the prostate . The key findings from our…

iFrame is not supported! Genomic-Adjusted Radiation Dose Explained [2022] What Is Genomic-Adjusted Radiation Dose (GARD)? Genomic-Adjusted Radiation Dose (GARD) is a mathematical formalism that allows radiation oncologists to translate how much dose comes out of the radiation machine and into the patient and translate that into how much that will affect an individual patient. And it does that through a genetic signature of the tumor genome. And I think to anyone who’s (patients) treated radiation patients or any patients in the past. We all know intuitively that the same (radiotherapy prescription) dose doesn’t do the same thing to…

iFrame is not supported! What is The FAST-01 Clinical Trial in FLASH Radiotherapy About? It’s radiation that’s delivered at ultra high dose rates. FAST-01: 2022 5 Key Takeaways Is it possible to relieve the discomfort caused by painful bone metastases in the extremities with proton FLASH irradiation, which is provided at a dose rate that is 1000 times higher than the dose rate of conventional-dose-rate photon radiotherapy? Proton FLASH was therapeutically feasible and safe, with reduced severity of side effects, as established by this nonrandomized RCT of 10 patients with bone metastases in the extremities. The pain-relieving efficacy of the…

Male Breast Cancer: Clinical Signs [2022] What Are the Signs of Male Breast Cancer? And why do they go undetected? I think one thing that people don’t realize is that guys can actually get breast cancer. It is a relatively rare diagnosis, but that being said, we still see it. I think in the United States, there are about 2 to 3000 cases reported every year in men that develop breast cancer. When it comes to symptoms of breast cancer, most men have a breast lump that can be felt right under the nipple. I would say occasionally…

Breast Density Notification Rule: 2022 FDA: Dense Breasts The FDA Is Updating the Notification Rule For Women With Dense Breasts There’s been a lot of discussion recently about women with dense breasts and hiding cancers and the potential need for adding additional screening tests and also some new rules that will be coming out from the FDA, and I wanted to talk with you all about that. We know that mammography alone works pretty well. We should start screening every woman at least by age 40 if she has an average risk of breast cancer, and we find…

Male Breast Cancer: Clinical Signs [2022] iFrame is not supported! What Are the Signs of Male Breast Cancer? And why do they go undetected? I think one thing that people don’t realize is that guys can actually get breast cancer. It is a relatively rare diagnosis, but that being said, we still see it. I think in the United States, there are about 2 to 3000 cases reported every year. When it comes to symptoms of breast cancer, most men have a breast mass that can be felt right under the nipple. I would say occasionally a man will…

iFrame is not supported! Plinabulin addition to the DUBLIN-3 was a randomized phase III trial from BeyondSprings Pharmaceuticals in non-small cell lung cancer. It looked at an advanced non-small cell lung cancer, EGFR wild type. And I was looking at second and third-line treatment. Patients had to progress through at least one line of therapy, but two lines of progression were okay. And patients had to have been exposed to platinum-based therapy. The randomized clinical trial was pretty broad in that it took patients with an ECOG performance status of 2 or better, and they had to have measurable disease…

Breast Density Notification Rule: 2022 FDA: Dense Breasts iFrame is not supported! The FDA Is Updating the Notification Rule For Women With Dense Breasts There’s been a lot of discussion recently about women with dense breasts and hiding cancers and the potential need for adding additional screening tests and also some new rules that will be coming out from the FDA, and I wanted to talk with you all about that. We know that mammography alone works pretty well. We should start screening every woman at least by age 40 if she has an average risk of breast cancer,…

iFrame is not supported! Does Atezolizumab SBRT Improve Progression-Free Survival In NSCLC? Atezolizumab is an immune checkpoint inhibitor that targets PDL-1. It has been studied in a number of solid tumors, including non-small cell lung cancer, and is an approved treatment for non-small cell lung cancer that has spread to other parts of the body. It was also recently found to improve progression-free survival in patients with early-stage non-small cell lung cancer whose cancer had been removed. So, in S1914, we’re testing to see if adding neoadjuvant, concurrent, and adjuvant Atezolizumab SBRT (stereotactic body radiation therapy) randomized phase III trial…

Does Atezolizumab SBRT Improve Progression-Free Survival In NSCLC? Atezolizumab is an immune checkpoint inhibitor that targets PDL-1. It has been studied in a number of solid tumors, including non-small cell lung cancer, and is an approved treatment for non-small cell lung cancer that has spread to other parts of the body. It was also recently found to improve progression-free survival in patients with early-stage non-small cell lung cancer whose cancer had been removed. So, in S1914, we’re testing to see if adding neoadjuvant, concurrent, and adjuvant Atezolizumab SBRT (stereotactic body radiation therapy) randomized phase III trial for people with early-stage…

iFrame is not supported! What is The Phase III REPLATINUM Clinical Trial In Small Cell Lung Cancer (SCLC)? Interesting question, RRx-001 was tested in the phase III REPLATINUM clinical trial. Is it a new compound, and what has it been used for? So the answer to that is, absolutely, it is a new compound. There is nothing else like it. It is a traditional alkylating agent. But then, on alkylating cystines, not DNA protein cystines, it converts to a biologic agent and actually releases nitric oxide. As you were asking, the thing that’s probably most similar to it would…

REPLATINUM Phase III Update [2022] What is The Phase III REPLATINUM Clinical Trial In Small Cell Lung Cancer (SCLC)? Interesting question, RRx-001 was tested in the phase III REPLATINUM clinical trial. Is it a new compound, and what has it been used for? So the answer to that is, absolutely, it is a new compound. There is nothing else like it. It is a traditional alkylating agent. But then, on alkylating cystines, not DNA protein cystines, it converts to a biologic agent and actually releases nitric oxide. As you were asking, the thing that’s probably most similar to it would…

Genomic-Adjusted Radiation Dose Explained [2022] What Is Genomic-Adjusted Radiation Dose (GARD)? Genomic-Adjusted Radiation Dose (GARD) is a mathematical formalism that allows radiation oncologists to translate how much dose comes out of the radiation machine and into the patient and translate that into how much that will affect an individual patient. And it does that through a genetic signature of the tumor genome. And I think to anyone who’s (patients) treated radiation patients or any patients in the past. We all know intuitively that the same (radiotherapy prescription) dose doesn’t do the same thing to each patient (radiotherapy benefit).…

Cribriform CAP Intraductal Carcinoma Prostate [2022] Cribriform Prostate Cancer Clinical Trial I’m here to talk about our recent study, presented at ASTRO’s annual meeting. In this study, the gene expression or transcriptome characteristics of aggressive prostate cancer were looked at and found to be linked. morphologic appearance under the microscope as characterized by our genitor urinary pathologists, who are primary co-authors on the study. In particular, they were looking at this aggressive morphology or morphology associated with aggressive clinical behavior called cribriform or intraductal cancer of the prostate . The key findings from our study were that in…

NRG / RTOG 1112 Phase 3 Trial: ASTRO [2022] Nrg/RTOG 1112 A Randomized Phase III Study The NRG/RTOG 1112 (NRG Oncology RTOG 112) clinical trial focuses on patients with hepatocellular carcinoma, a group of patients who are understudied and in need of better treatments. At the start of this study, sorafenib was the standard of care for patients treated with locally advanced hepatocellular carcinoma that could not be removed and did not respond well to standard local ablation therapies or hepatic arterial regional therapies like TACE. And so that is why sorafenib is the backbone systemic therapy that’s used in…

Prioritizing Screening Mammogram: Help Early Diagnosis? Mammography (breast imaging) is one of the most commonly used preventive healthcare services (annual mammogram). However, with the recent rise of breast cancer, more and more women are asking their doctors about screening annual mammograms (scheduling baseline mammograms). What is the difference between an immediate and a delayed mammogram? How should you go about choosing which type of mammography to have? This article will talk about these questions and give you some tips on how to decide which screening mammograms are most important and get a immediate mammographic interpretation. Screening mammograms (SMs) or Breast…

Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series focused on TNBC. This multidisciplinary tumor board discusses a patient with advanced TNBC and how novel anti-TROP2 antibody-drug conjugates (ADCs) therapy may play a role. Claim credit: https://www.achlcme.org/tnbc-case-challenge-onctube Access the three-part series: https://www.achlcme.org/triple-negative-breast-cancer

Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board!  The multidisciplinary panel of expert faculty will dive into a case involving a patient with early TNBC and discuss the latest data and potential roles of PARP inhibitors (PARPIs) in the first CME activity offered in this TNBC series. Claim credit: https://www.achlcme.org/PARPis-tnbc-onctube Access the three-part series: https://www.achlcme.org/triple-negative-breast-cancer

Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test in these interactive case challenges. As the third and final activity in the TNBC series, you will navigate through two cases. Education is built into the cases, on practical strategies to meet the treatment needs of diverse patients with TNBC. Access the full case study: https://www.achlcme.org/tnbc-case-challenge-onctube View the three-part series: https://www.achlcme.org/triple-negative-breast-cancer

With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a multidisciplinary team approach to caring for patients. As precision medicine continues to evolve in cancer care, the integration of pathologists within clinical care pathways to interpret test results and offer recommendations for biomarker testing aid in personalized treatment approaches. This series offers two interactive programs supported by audio and video commentary, where expert faculty share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:• Increase implementation of best practices for EGFR mutation…

rAd-IFNα/Syn3 Phase 3 Trial NMIBC [2022] rAd-IFNα/Syn3 Bladder Cancer Trial It’s an honor to be asked to speak about this medication, which is a very exciting new development for many patients with non muscle-invasive bladder cancer. So RAD interferon alpha CIN 3 is a compound that links. The adenoviral vector RAD alpha interferon to an excipient CIN 3, which helps transduction of the adenovirus into bladder cancer cells. So it is a new compound. It was developed in conjunction by Dr. Colin Denney from MD Anderson with FKD Therapeutics, a company in Finland. And it was, as we’ll talk…

CHECKMATE-914 Phase 3 Dr. Brian Rini, MD [2022] CHECKMATE-914 Trial The purpose of this study is to determine if the use of Nivolumab on its own or in combination with Ipilimumab and Nivolumab, as opposed to the use of a placebo, is both safe and beneficial for postponing or preventing the recurrence of cancer in patients who have had a kidney removed.   The key outcomes of this study are measured in two different ways. The first principal completion date is anticipated to take place in July 2022. (DFS in Part A). The second primary completion date is anticipated to…

Prophylactic management of hemophilia continues to be a challenge. This nurse-led activity discusses treatment strategies, safety and efficacy of current available products, and how to improve patient adherence.  In this clinical commentary, expert faculty, Kerry H. Hansen, RN, BS and Skye Peltier, MPH, PA-C review best practices to facilitate successful therapeutic interventions with hemophilia A prophylaxis. Claim credit: https://www.achlcme.org/hemophilia-a-prophylaxis-onctube

CHECKMATE-914 Phase 3 Kidney Cancer Trial [2022] CHECKMATE-914 Trial I’m going to talk to you today about CHECKMATE-914 clinical trial, which was an adjuvant study of Ipilimumab plus Nivolumab (in combination) in high risk resected kidney cancer.   The background of this study (CHECKMATE-914 trial) is that About a year or so ago, we had the first data for adjuvant (treatment) immun0therapy and kidney cancer (localized renal cell carcinoma RCC), which was from the keynote study of adjuvant Pembrolizumab versus placebo and resected, high risk localized kidney cancer. That study (CHECKMATE-914 trial) and its follow up showed a significant disease-free…

COSMIC-313 Phase 3 Kidney Cancer Trial [2022] COSMIC-313 Kidney Cancer Trial I’m going to talk today about COSMIC-313 ( Ipi/Nivo (Nivolumab and Ipilimumab)), which is a clinical trial just reported as more of the latest phase 3 data in advanced kidney cancer (advanced renal cell carcinoma).   The background of the COSMIC-313 ( Ipi/Nivo (Nivolumab and Ipilimumab)) study: this was a study looking at Ipi/Nivo (Nivolumab and Ipilimumab) as a comparison arm, which, as you probably know, are two immune therapy drugs that are a common frontline treatment (components) in advanced RCC (advanced renal cell carcinoma). And it was compared…

Breast Cancer Screening [2022]: What Are We Missing? Are Women Avoiding Breast Cancer Screening? Because of COVID-19 and the subsequent lockdowns, a significant number of women were either unable to get their yearly mammograms (primary breast cancer screening tests) or did not feel it was safe to get their regular screening. And why, if they were screened, do such a large number of women still lack a diagnosis? The concept that women with dense breasts are misidentified as having the condition was investigated further through these clinical studies. Screening with mammography according to industry standards is insufficient for early detection,…

UCSF With FDA In Robotic Colorectal Surgery Trial: da Vinci SP [2022]   The da Vinci SP Surgical Systems So the daVinci is the robotic platform for a company called Intuitive. The daVinci has been around since 1999 and has had several generations of robots. Their most recent generation, which is ubiquitous around the US and increasingly being picked up around the world, is called the XI platform, and this is a multiport platform.   There are two types, one has four robotic arms. I can show a picture if you are interested. But it has four arms that go…

Shahid Gilani, MD, Specialist doctor in Clinical Oncology from University Hospital of North Midlands, speaks about the Cancer Associated Thrombo-prophylaxis. Dedicated Cancer Associated Service @UNHM_NHS @sngilani

SWOG S1801 Trial: Pembro After or Before Surgery? [2022] It is not yet known which type of immunotherapy, adjuvant or neoadjuvant, is more effective in the treatment of high-risk melanoma; this question has not been answered. The findings of this trial provide additional evidence regarding the conditions under which one approach might be more beneficial than the other.    It has been demonstrated that neoadjuvant immunotherapy can induce spectacular complete pathologic responses, which, up until this point, have been associated with a sustainable response. Patients with clinically detectable high-risk melanoma (that have received prior radiation therapy) are more likely to…

M14TIL Trial: TIL Compared to Std. Ipilimumab [2022] This is the first experiment to use tumor-infiltrating lymphocytes (TIL) in metastatic cancer. The results have shown an advantage in progression-free survival (PFS). The findings of this clinical trial may serve as a springboard for additional research into the use of TIL in other forms of cancer, with the potential to demonstrate benefit in a wide variety of other solid tumors and to increase the number of therapy options accessible to patients (treated with TIL). While immunotherapy can provide spectacular long-term responses, a significant portion of patients treated will have no response…

Shahid Gilani, MD speaks about Cancer‐Associated Thrombosis (CAT), Emerging Concepts and Paradigm shift, in Grand Round at University Hospital of North Midlands, United Kingdom. Dedicated Cancer Associated Service @sngilani

PRO in Pts With Rare Cancers: Pembrolizumab [2022]   Patient reported Outcome (PRO) in patients with rare cancers (rare diseases) treated with Pembrolizumab. Pembrolizumab’s acceptability and safety are being investigated in this study. The clinical benefit grade, as well as the objective (objectively measured) response. This phase to study, which was published in the Journal For Immunotherapy of Cancer in 2020, showed that Pembrolizumab has a favorable toxicity profile and anti-tumor activity in patients (and their clinical care) with rare cancers (rare diseases) such as squamous cell carcinoma of the skin, carcinoma of unknown primary and adrenal cortical carcinoma, paraganglioma,…

Shahid Gilani, MD from the University Hospital Of North Midlands speaks about Hypofractionated radiotherapy as a definitive treatment for Basal Cell Carcinoma: A single-institution experience. Hypofractionated RT in BCC Oncologytube BIR conference 2021 @sngilani @UHNM_NHS

Shahid Gilani, MD, Specialist doctor in Clinical Oncology from University Hospital of North Midlands, speaks about the management of Bone Health monitoring in Early Breast Cancer Patients recieving aromatase inhibitors. . ESMO Breast 2022- Bone Mineral Density screening and monitoring in EBC patients. @sngilani @UHNM_NHS

DASL-HiCaP Phase 3 Trial [2022]: Update David Wise MD   David Wise, MD Spoke with OncologyTube about the DASL-HiCaP (randomised) Phase 3 Trial The DASL (DASL-HiCaP) (randomised phase 3 clinical trial) trial. It’s one of the key trials going on right now in the non-metastatic space. And we need a lot more innovation for non-metastatic prostate cancer (or very high risk cancer). Of course, patients with this non-metastatic cancer have a far longer life expectancy and do well.   But we still certainly need to do better. And I think that Darolutamide or NUBEQA as the brand name is certainly…

Lutetium-177–PSMA-617 [2022]: Update David Wise MD   So Lutetium-PSMA-617 ((lu psma 617) prostate specific membrane antigen), we’ll call it 617 for this discussion, is already an FDA-approved agent for Progressive Metastatic Castrate Resistant Prostate Cancer (MCRPC metastatic castration resistant prostate cancer or advanced prostate cancer). The brand name is Pluvicto. The FDA approval is for men who have progressed despite 1 prior advanced hormonal therapy and at least 1 prior line of Taxane therapy.     And that agent is quite active and well tolerated. The question remains: How and in what is the best way to move this agent…

PROTECTIVE-2 Phase 3 Trial [2022] Update   Is Plinabulin a new compound? Has it been used in other disease states? Plinabulin is a small molecule. It’s a new compound. It is not yet approved. The program started as an anti-cancer program because Plinabulin has anti-cancer activity. In our phase 2 study with non-small cell lung cancer patients, we unexpectedly observed a benefit with chemo-induced (severe) neutropenia (chemotherapy induced neutropenia CIN, an adverse event). The chemo used for that was Docetaxel. Plinabulin is an anticancer agent that also has a benefit of preventing neutropenia.   And that then became a separate…

ASCO [2022] Lung Cancer In-Depth Slides: MOASC Dr. Misako Nagasaka’s (thoracic oncology) MOASC Presentation on ASCO (Annual Meeting, American Society of Clinical Oncology) 2022 ((Advanced Non) Small Cell) Lung Cancer (Trial) Thank you so much. For the opportunity today, I’m Misako Nagasaka, I’m from UC Irvine, in thoracic (clinical) oncology. Today, I will be talking about updates from ASCO 2022 (lung cancer), but in the interest of time and because of my interest, I will be focusing my talk on lung cancer for targeted therapies for (advanced) non-small cell lung cancer. Here are my disclosures. So here is…

ASCO (American Society of Clinical Oncology) [2022] Sarcomas Cancer In-Depth Slides: MOASC   Dr. Warren Chow’s MOASC Presentation on ASCO 2022 Sarcoma Cancer So I also wanna thank Jason and the organizers of MOASC (ASCO 2022 sarcoma cancer (American Society of Clinical Oncology) update) for inviting me. I’m feeling my age because I see a lot of my former fellows in academia and pharma and in practice here. These funny stories are that when I was at city hope with Joe Chao, he used to be called young Chao, and I was called old Chow.   Now I’m very old…

SOLO-1 Phase 3 [2022]: Newly Diagnosed Advanced Ovarian Cancer Research   Dr. Greg Rossi talks with OncologyTube about the SOLO-1 Phase III Trial The history of Lynparza, Olaparib, and PARP inhibitors stretches back really a couple of decades in cancer research. We had an observation a number of researchers an observation that we could target the DNA damage responses, and pathway of tumor cells as a therapeutic target, and with Olaparib, we’ve been able to do that in not just ovarian cancer, but actually in breast cancer, prostate cancer, and in pancreatic cancer.   And it really harnesses the approach…

Question and Answer Session Dr. Misako Nagasaka – ASCO [2022] Lung Cancer In-Depth Slides: MOASC Presentation https://oncologytube.com/v/41320 Misako Nagasaka, MD – About The Author, Credentials, and Affiliations At the University of California in Irvine, Dr. Nagasaka is a board-certified thoracic oncologist who specializes in the detection and treatment of lung and thyroid cancer. He also treats patients with other types of thoracic cancer. In addition to that, early-phase clinical studies, medical ethics, and survivorship care for patients are some of her clinical interests. She attended the St. Marianna University School of Medicine in Kawasaki, Japan, where she was awarded both…

Question and Answer Session Kay Yeung, MD, Ph.D. – ASCO [2022] Breast Cancer In-Depth Slides: MOASC https://oncologytube.com/v/41294 Kay Yeung, MD, Ph.D. – ASCO [2022] Breast Cancer Overview: MOASC Spotlight https://oncologytube.com/v/41282 Kay Yeung, MD, Ph.D. – About The Author, Credentials, and Affiliations Her primary area of expertise is in the clinical oncology treatment of breast cancer patients, for which she holds board certification. In order to provide patients with the most effective range of treatment options, she employs a variety of therapeutic approaches, including endocrine therapy, chemotherapy, targeted therapy, and immunotherapy. She is also a teacher at the UC San Diego School…

Question and Answer Session Justin Moyers, MD – ASCO 2022 Melanoma Overview: MOASC Spotlight https://oncologytube.com/v/41283 Justin Moyers, MD Exit Interview  https://oncologytube.com/v/41283 Zachary Hanson, DO – Anemia and Zinc Deficiency [2022]: MOASC Spotlighthttps://oncologytube.com/video/41301 Justin Moyer, MD- About The Author, Credentials, and Affiliations Medical oncologist and assistant clinical professor of medicine at the University of California, Irvine School of Medicine Justin T. Moyers is board certified in medical oncology and works at the University of California, Irvine Medical Center.   His clinical practice interests include skin cancers. Melanoma is another one of his clinical (oncology) specialties. His research interests include both the…

Question and Answer Session Joseph Chao, MD – ASCO 2022 Esophageal In-Depth Slides: MOASC Spotlight https://oncologytube.com/v/41288 Joseph Chao, MD – About The Author, Credentials, and Affiliations Joseph Chao, MD, one of Pasadena magazine’s “Top Doctors” for oncology since 2011, joined the City of Hope as a resident of oncology in 2007 and was appointed as an assistant professor with a specialty in stomach and esophageal (gastric cancer) malignancies in 2010.   Currently, he is heading clinical trial efforts to find novel therapeutics for gastroesophageal malignancies and undertaking studies to gain a better understanding of intratumoral heterogeneity in this illness.  …

Question and Answer Session   Warren Chow, MD – ASCO [2022] Sarcomas Cancer In-Depth Slides: MOASC https://oncologytube.com/v/41319 Warren Chow, MD – About The Author, Credentials, and Affiliations Dr. Warren A. Chow is an oncologist at UCI Health who is board-certified and specializes in treating patients who have melanoma and sarcoma. At the Chao Family Comprehensive Cancer Center at the University of California, Irvine, he will work as the cancer clinical sciences associate director.He attended Chicago Medical School, which is now part of Rosalind Franklin University of Medicine and Science and is located in North Chicago, Illinois. This is where he…

Question and Answer Session Arash Rezazadeh, MD, ASCO [2022] Genitourinary Cancer: MOASC Oncology Spotlight Link https://oncologytube.com/v/41291 Arash Rezazadeh, MD, ASCO 2022 Prostate Cancer Overview: MOASC Spotlight Link https://oncologytube.com/v/41285 Arash Rezazadeh, MD – About The Author, Credentials, and Affiliations Dr. Arash Rezazadeh is an Associate Clinical Professor in clinical oncology at UCI Health and a medical oncologist who focuses their practice on the treatment of urologic malignancies.

Shahid Gilani, MD, Specialist doctor in Clinical Oncology from University Hospital of North Midlands, speaks about the management of Cancer Associated Thrombosis (CAT) in a dedicated service. Cancer is the highest single risk factor for thrombosis therefore the CAT service will play an important role in improving both the outcomes and quality of life in cancer patients. A dedicated team manages cancer patients with thrombosis and in need of anticoagulation ensuring that patients get assessed, diagnosed and treated along with patient education and support they need. @sngilani @UHNM_NHS dedicated CAT Clinic

Question and Answer Session  May Cho, MD – ASCO 2022 Colon Cancer In-Depth Slides: MOASC Spotlight Link https://oncologytube.com/v/41298 May Cho, MD – ASCO 2022 Colon Cancer Overview: MOASC Spotlight Link https://oncologytube.com/v/41284 May Cho, MD – About The Author, Credentials, and Affiliations Medical oncologist at UCI Health specializing in the diagnosis and treatment of gastrointestinal cancers (gastrointestinal oncology) (colorectal cancer), Dr. May T. Cho, holds board certification in her clinical oncology field and has extensive experience in the field. She has spent a considerable amount of time working with UCI Health.

Visit http://ecancer.org/ for more. Dr Gilani (University Hospital of North Staffordshire, Stoke-on-Trent, UK) talks to ecancertv at ASCO 2014 about the effects of chemotherapy exposure in pregnant women and the regulations, or lack thereof, that protect female employees from risk. @sngilani @UHNM_NHS

Anemia and Zinc Deficiency [2022]: MOASC Spotlight   Zachary Hanson, DO MOASC Poster on Anemia Zinc Deficiency 2022 Hi, I’m Dr. Zachary Hanson from Loma Linda University Medical Center under the direction of Dr. Tari in the medical cancer center. I’ve done a research project I’d love to present to you guys. And so what we’ve done is we’ve done a retrospective review of patients with chronic anemia that was also found to have a (mild) zinc deficiency.   And so what we’ve done is we’ve looked at these patients with (severe) zinc deficiency supplemented with supplemental zinc (intake for…

Cancer and COVID-19: Thrombosis and Pro-inflammatory (cytokines)   Christopher Grant, MD, MOASC Poster on Cancer and COVID-19: Thrombosis and Pro-inflammatory Cytokines Hello, my name is Chris Grant. I’m a PGY two at UC Irvine and have an internal medicine residency. And I’d like to present my poster today on thrombosis and pro-inflammatory cytokines responses in COVID-19 with cancer at a tertiary cancer center. And so, just to begin, C is known to have many numerous coagulable factors that actually reach into that pro-inflammatory cytokine state in the OSE triad paired with that cancer also has many of those properties as…

Paraneoplastic Glomerular Nephropathy [2022]: MOASC   Xiaojie Zhang, MD Poster On Paraneoplastic Glomerular Nephropathy Hi, I’m Xiaojie Zhang, and I’m a first-year hematology-oncology fellow at the University of California San Diego. My poster today is about paraneoplastic glomerular nephropathy associated with renal cell carcinoma. This is an observational analysis of case reports published in the last four decades of patients with PGN associated with a diagnosis of renal cell carcinoma. What is PGN (paraneoplastic glomerular disease)? PGN (paraneoplastic glomerular diseases) is a rare manifestation or rare type of paraneoplastic syndromes, which is associated with a variety of solid tumors. Among…

ASCO 2022 Colon Cancer In-Depth Slides: MOASC Spotlight   May Cho, MD from UCI Health ASCO (American Society of Clinical Oncology) Annual Meeting Presentation   I have to start with this neoadjuvant and definitive immunotherapy in MSI high (locally advanced) rectal cancer (gastrointestinal cancers) (colorectal cancer), especially in localized disease with the New York time Arteris of full messages, exponential like a hundred times. And then, I will go over the role of CMMRD in the management of early-stage colon cancer (colorectal cancer, rectal cancer).   And finally, I will conclude the outcomes with optimized first-line therapy in metastatic colorectal…

This immersive practice guide offers “how to” methods and day-to-day strategies via faculty commentary and a review of data and guideline recommendations. Expert faculty address which approaches may not be working, complexities in managing this patient population, insights on how the latest evidence supports a practical recommendation and review available therapies to optimize treatment selection.   Claim credit: https://www.achlcme.org/multiple-myeloma-onctube

ASCO [2022] Breast Cancer In-Depth Slides: MOASC   Kay Yeung, MD, Ph.D. Delivers Her MOASC 2022 Breast Cancer Presentation Hello, everyone. Thank you for inviting me. And have the opportunity to really go over some breast cancer (care) updates and definitely a lot of excellent breast cancer presentations and breast cancer abstracts that was presented in 2022 ASCO (this year’s American Society of Clinical Oncology) annual meeting today this year. And I don’t have time to go over all of them, but I hope that the ones I go over will be interesting and important.   So this is my…

GI Genius vs Standard Colonoscopy: Is it Better?   Rosario Ligresti, MD, FASGE Speaks About The GI Genius Intelligent Endoscopy Module (colon cancer) For many years, colonoscopy has been considered the gold standard for colon and rectum cancer screening. And we know, based on many years worth of data suggesting how accurate colonoscopy is. But when you actually dive down somewhat more deeply between the lines, you find out that colonoscopy, as we practice it currently, may not be as accurate as intended, with potentially missed colorectal polyps. You consider some of the more recent reviews of colonoscopy and where…

Pediatric Patients with CGvHD Ibrutinib OK’d by FDA   Chronic graft versus host disease, or CGvHD, is a condition associated with immune dysregulation that can occur about 100 days post an allogeneic stem cell transplant.   It is multisystemic. It usually occurs in the skin, the liver, the GI tract, the eyes, and the lungs so that it can be all-encompassing.   It is the leading cause of non-relapse mortality, and it is generally associated with delayed immune reconstitution, as well as infections. In the pediatric world, it can have a lower incidence versus the adult world.   However, the…

ASCO [2022] Genitourinary Cancer(s): MOASC Oncology Spotlight Dr. Arash Rezazadeh’s MOASC 2022 Presentation in Genitourinary Cancers (ASCO genitourinary cancers symposium) ARASENS Trial – In Patients with Metastatic Castration Sensitive Prostate Cancer(s) (Genitourinary Cancers) ARASENS (retrospective study) was one dataset that may change the standard of care for some of the patients with prostate cancer(s). So I picked that for that reason. It’s Darolutamide versus placebo in combination with ADT docetaxel. So remember the. The standard of care in this trial was defined as ADT plus Docetaxel, and it was in patients with metastatic castrate sensitive. Prostate cancer(s) (castration resistant prostate…

ASCO 2022 Melanoma (American Society of Clinical Oncology) In-Depth Slides: MOASC Spotlight on Oncology I’ll do a brief reminder of standard treatment options and then go over the DREAMseq trial and the RELATIVITY-047 and then if there’s time, if I was adequately caffeinated or something, we’ll also go onto the KEYNOTE-716 in the PRADO clinical trials in clinical oncology that may provide new evidence (additional information). Is two better than one? Current Standard of Melanoma Treatment Is two better than one? The current standard of care was based on the CheckMate 067 trial, where there were 3 arms. 945 patients…

ASCO 2022 Esophageal In-Depth Slides: MOASC Spotlight   ASCO 2022 Esophageal Cancer Abstracts Highlights Abstracts of interest that were recently presented at ASCO (gastrointestinal cancers symposium) just this past summer, the first is the randomized phase 2 DANTE trial in clinical oncology. So I think all of us are aware of our non-metastatic patients, but locally advanced and, unfortunately in the US, because of lack of effective screening strategies, a lot of our patients, even if they’re at least diagnosed without stage 4 disease, they typically have a very bulky disease that needs perioperative chemotherapy (systemic therapy). How can this…

Cholangiocarcinoma: Ipilimumab and Nivolumab Combo   MOASC Poster Session 2022 (Cholangiocarcinoma Ipilimumab Nivolumab) Hello, my name is Dalia Kaakour (clinical oncology). I’m a PGY three internal medicine resident at the University of California Irvine. And today, I’ll be presenting a poster. It’s actually a case series on three patients (patient population) with advanced cholangiocarcinoma, to who we saw durable responses to dual age it immunotherapy with ipilimumab and nivolumab.   So what’s unique about this case series is that it provides three examples of patients that were that are still seeing responses to this combination immunotherapy (with nivolumab) after having…

Despite the advances in precision medicine for non-small cell lung cancer (NSCLC), a significant proportion of patients, particularly African American and Hispanic patients, face inequities with access to these health breakthroughs. In this activity, expert faculty focus on the latest evidence with NSCLC disparities of care and how to best overcome these barriers. The activity also reviews how to assess opportunities to increase referral of minority patients to clinical trials and how to optimize overall care coordination among minority patients with NSCLC. Claim credit: https://www.achlcme.org/reduce-health-disparities-nsclc-onctube

ASCO 2022 Prostate Cancer Overview: MOASC Spotlight   ARASENS Trial I presented at MOASC three datasets in prostate cancer from the 2022 ASCO annual meeting. The first dataset was in metastatic castration-sensitive prostate cancer, the so-called ARASENS trial phase III study.   And we presented the data with ADT plus docetaxel plus dose AEL plus minus Darolutamide. These patients continue to get the triplet or doublet until the metastatic disease progression (cancer) or has unacceptable toxicity (management).   And then, we showed that there was an overall survival benefit in a subset of patients with de novo metastatic disease or…

ASCO (American Society of Clinical Oncology) 2022 Colon Cancer Overview: MOASC Spotlight   Today I presented three clinical trials at the American Society of Clinical Oncology (ASCO) annual meeting. The first one is neoadjuvant immunotherapy in locally advanced rectal cancer (colorectal cancer). That data was presented by MSK Group and given neoadjuvant immunotherapy for six months, giving a hundred percent clinical complete response rate or response duration in locally advanced rectal cancer care (colorectal cancer) patients. They don’t need to do any traditional chemotherapy, radiation, or surgery. They will just observe for now.    DYNAMIC trial The second topic is…

ASCO 2022 Melanoma Overview: MOASC Spotlight   KEYNOTE-716 Study   Today, we talked about some of the exciting new discoveries that have been made with melanoma abstracts or clinical trial(s) over the course of the past year, at the ASCO 2022 annual meeting. The first thing that we did was look at the KEYNOTE-716 research presented at ASCO 2022 (melanoma), which was a comparison between using pembrolizumab as an adjuvant treatment and using a placebo. The stage 2 melanomas were the primary focus of the study.   And the recurrence-free survival rate for pts with stage 2B and stage 2C…

ASCO 2022 Breast Cancer Overview: MOASC Spotlight   DESTINY-Breast04 Data from ASCO 2022 Annual Meeting I presented a lot of data today because such exciting results came from 2022 ASCO annual meeting to this year. I first presented DESTINY-Breast04 studies, which showed. Significant improvement in progression-free survival and overall survival (OS) for HER2 positive breast cancer, in breast cancer research. Her2-Low metastatic breast cancer in a subset analysis or exploratory analysis in the hormone receptor (HR) negative, HER2-Low metastatic breast cancer patients. We did also see a benefit improvement in PFS and OS, even though it’s a small group of…

Olaparib Approved In Japan: Breast Cancer   Olaparib’s Study Design For BRCA1 or BRC2 Variants in Early Breast Cancer OlympiA was a global double-blind placebo-controlled randomized phase 3 trial that evaluated the efficacy and safety of one year of adjuvant Olaparib versus placebo in adult patients with germline pathogenic, BRCA1 or BRC2 breast cancer variants who had completed standard chemotherapy administered either as adjuvant or neoadjuvant therapy and had surgery and radiation therapy if needed for what needed to be a, at least a high risk early breast cancer or two negative stages of early breast cancer.   What About…

T-DXd HER2-Positive Breast Cancer: DESTINY-Breast03 DESTINY-Breast03 Phase 3 clinical trial Study Design for HER2-Positive Breast Cancer This was a safety update from the DESTINY-Breast03 Phase 3 clinical trial, and as everyone is aware, trastuzumab deruxtecan, which is a medicinal conjugate consisting of an antibody, was approved for patients with HER2-positive metastatic breast cancer. This medication was included in the earlier line setting because of the DESTINY-Breast01 and DESTINY-Breast03 studies. Patients in the second-line scenario who have previously been treated with trastuzumab and/or taxane in a metastatic disease setting or who have experienced a rapid relapse within six months of completing…

Calquence Tablet FDA Approved CLL, SLL, MCL Can You Tell Us The Significance Of The FDA’s Approval Of Calquence? The new Calquence tablet formulation provides an oral treatment option for physicians to consider for their patients in the US for chronic lymphocytic leukemia, small lymphocytic leukemia and patients with mantle cell lymphoma who have received at least one prior treatment option. Twenty to forty percent of patients with hematologic malignancies receive a gastric reducing agent, of which 70% of those are proton pump inhibitors (PPIs). Now, patients on a proton pump inhibitor can receive Calquence without having to change their…

NRG-GI008 (CIRCULATE-US) Colon Cancer Overview [2022] To watch Dr. Arvind Dasari discuss the NRG-GI008 presentation with slides, Click Here! NRG-GI008 (CIRCULATE-US) is really seeking to answer the question. Can circulating tumor DNA be used to guide therapy for lower risk stage III colon cancer? Now we know that circulating tumor DNA has really been a game changer in terms of how we learn more about not only the genomics of the cancers that we have but if there’s minimal residual disease still left in the body. But of course, part of the problem with knowing if there’s molecular presence of…

1992: Lung Cancer Action Project studies Chest CT Scan for Early Detection of Lung Cancer When we started the Early Lung Cancer Action Project (ELCAP) in 1992, chest CT (computed tomography) scanners were strong and powerful enough that they could acquire all the images of your lungs in a single breath hold. At that point, we decided that we could look at chest x-ray and a chest CT scan to determine how much earlier the chest CT scan allowed us to detect lung cancer in comparison to standard x-rays (lung cancer screening). Chest CT scanners first became available in the…

NRG-GI008 (CIRCULATE-US) Colon Cancer Overview [2022] To watch Dr. Arvind Dasari discuss the NRG-GI008 presentation with slides, Click Here! NRG-GI008 (CIRCULATE-US) is really seeking to answer the question. Can circulating tumor DNA be used to guide therapy for lower risk stage III colon cancer? Now we know that circulating tumor DNA has really been a game changer in terms of how we learn more about not only the genomics of the cancers that we have but if there’s minimal residual disease still left in the body. But of course, part of the problem with knowing if there’s molecular presence of…

Is Interstitial Lung Disease a Manageable Adverse Event of Trastuzumab T-DXd Deruxtecan Treatment? What is Trastuzumab T-DXd? Trastuzumab T-DXd is an antibody-drug conjugate that consists of an antibody that binds to the HER-2 receptor that can be over-expressed or mutated in several different cancers. That is covalently linked to a payload. In this case, it’s a topoisomerase one inhibitor, a very potent chemotherapeutic drug, which has high toxicity typically when administered systemically. So there are advantages to the antibody-drug conjugate approach so that the payload is delivered preferentially to cells that express the HER-2 receptor. When the antibody-drug conjugate binds…

Are you aware that Black men continue to suffer worse outcomes compared to White men with prostate cancer? Through this education, learners improve their ability to recognize systemic, behavioral and sociocultural factors creating disparate health outcomes in prostate cancer, improve identification of patients at risk, and expedite time to diagnosis and time to treatment.   Access the toolkit: https://www.prostatecancerdisparities.org/ Claim credit: https://www.achlcme.org/reduce-prostate-cancer-disparities-onctube

FRESCO-2 Trial Met Primary Endpoints in Patients With Metastatic Colorectal announced HUTCHMED from the Fruquintinib Global Phase III Trial The FRESCO-2 trial was a Phase 3 clinical trial that has been specifically created for patients that were previously treated with surgically unresectable metastatic colorectal cancer therapy. It was basically a 2:1 randomization for patients that had received prior standard chemotherapy and previously treated metastatic colorectal with Regorafenibor and Lonsurf. Patients may have been exposed to Regorafenib or Lonsurf or both of the drugs and the primary endpoint was overall survival. Just to keep things in perspective for patients, we tend…

In this panel discussion and workshop, experts from the University of Chicago Medicine and the University of Illinois Cancer Center discuss structural racism and disparities faced by women receiving breast cancer care. Discussion is centered around strategies to address these disparities. The experts are also joined by patient advocates sharing their personal experiences and how providers can provide support. This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of…

In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses the oncology, surgical, and radiation treatment experiences of white and Black women. Dr. Chen also reviews barriers, common misconceptions with breast cancer treatment, and interventions clinicians can employ to overcome racial disparities in breast cancer. This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women…

In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses screening and mammography rates among racial/ethnic groups. Dr. Chen also touches on the impact of the COVID-19 pandemic, factors that influence disparities such as fears and misperceptions, the underutilization of genetic counseling and testing, and the importance of patient communication and navigation. Learn how you can address disparities in your own patient care. This activity was included in a series of workshops as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP,…

Listen as Amanda Kaczerski and Mahire Bonomo, Executive Director at the Center for Continuing Medical Education at The University of Chicago discuss getting a QI program off the ground. The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how strategies applied at a local level can address disparities in care. The project, led by renowned faculty Olufunmilayo Olopade, MD, FACP, is studying the effectiveness of targeted interventions in improving various facets of breast cancer care for African American women treated in Cook County. To learn more, visit fightingBCdisparities.com

The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how strategies applied at a local level can address disparities in care. The project, led by renowned faculty Olufunmilayo Olopade, MD, FACP, is studying the effectiveness of targeted interventions in improving various facets of breast cancer care for African American women treated in Cook County. To learn more, visit fightingBDdisparities.com

Dr. John Stewart from the Louisiana State University School of Medicine discusses navigating complex treatment. The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how strategies applied at a local level can address disparities in care. The project, led by renowned faculty Olufunmilayo Olopade, MD, FACP, is studying the effectiveness of targeted interventions in improving various facets of breast cancer care for African American women treated in Cook County. To learn more, visit fightingBCdisparities.com

The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how strategies applied at a local level can address disparities in care. The project, led by renowned faculty Olufunmilayo Olopade, MD, FACP, is studying the effectiveness of targeted interventions in improving various facets of breast cancer care for African American women treated in Cook County. To learn more, visit fightingBCdisparities.com

Dr. Monical Peek from The University of Chicago discusses women’s fears and racial health inequities as part of a quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women treated in Cook County. Learn more at fightingBCdisparities.com

The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how strategies applied at a local level can address disparities in care. The project, led by renowned faculty Olufunmilayo Olopade, MD, FACP, is studying the effectiveness of targeted interventions in improving various facets of breast cancer care for African American women treated in Cook County. To learn more, visit fightingBCdisparities.com

Lisocabtagene Maraleucel has been approved by the FDA for the second-line treatment of large B cell lymphoma LBCL Lisocabtagene Maraleucel Key Statistics: 65% risk reduction of event-free survival in the Lisocabtagene Maraleucel arm. 10.1 months (95% confidence interval: 6.1, not evaluable) estimated median event-free survival compared to 2.3 months (95% confidence interval: 2.2, 4.3). 59% risk reduction in progression-free survival in the Lisocabtagene Maraleucel arm compared to standard of care. Lisocabtagene Maraleucel is not approved to treat people with primary central nervous system lymphoma. Hazard ratio (HR) of 0.34 (95% CI:0.22, 0.52; p-value0.0001), event-free survival was substantially longer in the…

Hepion Pharmaceuticals Inc Lead Therapy, Rencofilstat Approved for FDA Orphan Drug Designation   Some of the leading causes of liver cancer, which is called Hepatocellular Carcinoma, we call it. Oftentimes, just because HCC is a bit of a multiple, we just refer to it as HCC. You hear me talking about the treatment of Hepatocellular Carcinoma (HCC), one of the leading causes of HCC development. In the Western world, particularly if we look at the US or look at parts of Europe, the leading cause would be something called NASH. What is NASH? NASH is another liver disease. NASH stands…

Dr. Nan Chen from the University of Chicago Medicine shares a status update from ASCO on the quality improvement program “Leading the Way: Improving Breast Cancer Disparities for Minority Patients in Chicago.” Led by Olufunmilayo Olopade, MD, FACP, this initiative is studying the effectiveness of targeted interventions in improving breast cancer care for African American women treated in Cook County.Learn more at fightingBCdisparities.com

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the ALK/ROS1 breakout session, Drs. Jessica Lin and Chul Kim discuss what is known about bypass mechanisms (PIK3, MEK, ERK, etc). A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the ALK/ROS1 breakout session, Drs. Jessica Lin and Chul Kim discuss what treatment options are available for ROS1 and ALK cancer that transforms to a neuroendocrine tumor. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Dr. Lyudmila A. Bazhenova discusses KRAS-directed therapies. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Dr. Millie Das discusses new therapies in NTRK, RET, and HER2. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss what makes mutations vary. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss how a patient with a designated KRAS mutation ensures the best treatment. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss how a patient can go about applying for a trial if their physician isn’t advocating for it. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join…

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss the trials available for NTRK resistant mutation. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss what treatment options are available for KRAS K12c Mutation in NSCLC. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss if a patient can have multiple mutations and if so, how they are treated. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit…

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss the difference between tissue and liquid biopsies. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss whether a patient whose tumor has been removed should get molecular testing. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss what is the recommended first-line treatment for KRAS K12c? A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the KRAS and Rare Tumor breakout session, Drs. Lyudmila A. Bazhenova and Millie Das discuss recommendations on whether or not to wait for an NGS panel result for a newly diagnosed patient with a 90% PDL1 expression. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more,…

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the PM session of the event, Drs. Ben Levy, Jack West and Zosia Piotrowska discuss if there is ever a role for single-agent immunotherapy in driver mutation-positive patients. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the PM session of the event, Drs. Ben Levy, Jack West and Zosia Piotrowska discuss first treatment recommendations for a patient with KRAS G12c, heavy smoker with 90% PDL1 expression. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation,…

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the PM session of the event, Drs. Ben Levy, Jack West and Zosia Piotrowska discuss if there is a role for chemo plus immunotherapy in patients with EGFR Mutations and if so, when? A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To…

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the PM session of the event, Drs. Ben Levy, Jack West, and Zosia Piotrowska discuss if there will ever be an Opportunity to Use TKI + IO together. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the PM session of the event, Dr. Jared Weiss discusses the role of chemotherapy in driver-positive patients. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the PM session of the event, Dr. Zosia Piotrowska discusses genotype-directed therapies and their role in earlier-stage disease. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the PM session of the event, Dr. Ticiana Leal discusses targeted therapies in oligometastatic disease. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time. For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty. In this video, from the PM session of the event, Gina Hollenbeck discusses online communities and support, and the importance of education and partnership in research. A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss molecular testing in potentially resectable NSCLC and unresectable locally advanced NSCLC. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join…

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss molecular testing and differences by histology and/or smoking status. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join the conversation,…

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss broad moleular testing in stage lll unresectable disease. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join the conversation, visit…

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss molecular testing, PDL1 and Imfinzi/Durvalumab. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss immunotherapy in PDL1 and EGFR. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss anticipated surgery and the effect on a pneumonectomy recommendation. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join the conversation,…

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss surgical vs non-surgical treatment in early nsclc. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss neoadjuvant therapy vs. adjuvant therapy, and where it fits now. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join the…

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss the future role of neoadjuvant therapy vs. adjuvant therapy. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join the conversation,…

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss circulating tumor DNA for minimal residual disease. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the AM Panel discussion on Early Stage NSCLC with H. Jack West, MD, and Drs. Estelamari Rodriguez, Riyaz Shah, and Narjust Duma, the doctors discuss if we should extrapolate across molecular markers in a curative setting. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join…

OncTalk 2021, a live-online, patient education event featured top oncologists discussing Early Stage and Advanced Non-Small Cell Lung Cancer. This event was chaired by Ibiayi Dagog-Jack, MD, with co-chair H. Jack West, MD. For the full agenda, https://cancergrace.org/onctalk-2021-agenda, and for information on the faculty, https://cancergrace.org/onctalk-2021-faculty-bios. In this video, from the second-panel discussion on Advanced NSCLC with Ibiayi Dagogo-Jack, MD, and Drs. Melina Marmarelis, Adrian Sacher, and Aparna Hegde, the panel discuss if broad next-generation sequencing (NGS) is the standard of care. A huge thank you to our sponsor! #takedaoncology For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Jared Weiss discusses the superior prognosis for HPV-driven head and neck cancers, and their candidacy for reduced intensity. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Many thanks to our sponsor #merck!

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Jared Weiss makes an argument for reducing the intensity of treatment in some SCCHN patients. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Many thanks to our sponsor #merck!

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Jared Weiss discusses avoidance of adjuvant radiation treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Many thanks to our sponsor #merck!

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Jared Weiss discusses how deintensification affects the current standard of care. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Many thanks to our sponsor #merck!

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Wendell Yarbrough discusses HPV and smoking-related head and neck cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Many thanks to our sponsor #merck!

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Wendell Yarbrough discusses the prevalence of HPV-related head and neck cancers, and how to prevent them. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Many thanks to our sponsor #merck!

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Wendell Yarbrough discusses three main treatments of HPV+ Head and Neck Cancers, as well as their side effects. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Many thanks to our sponsor #merck!

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Wendell Yarbrough discusses changes in the dose and field of radiation treatment for head and neck cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsor #Merck!

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Wendell Yarbrough discusses using induction to guide radiation. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thanks to our sponsor #Merck!

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Wendell Yarbrough discusses using surgery as a tool to determine radiation usage. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thanks to our sponsor #Merck!

We are pleased to share updates to the GRACE Patient Education Program on HPV Advances. In this video, Dr. Wendell Yarbrough discusses what factors determine if a patient qualifies for de-escalation. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsor #Merck!

We are proud to present this series on Clinical Trials Experiences. This unique patient education program gives a voice to patients with experience in participating in a clinical trial. Through storytelling and sharing their experiences, patients can educate others who are considering a similar journey. In this first video, Melinda Bachini, a 12-year survivor of cholangiocarcinoma discusses her diagnosis and her next steps for dealing with the treatment of this rare cancer. Many thanks to our sponsors! #Exelixis #Novartis #Merck #Lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

We are proud to present this series on Clinical Trials Experiences. This unique patient education program gives a voice to patients with experience in participating in a clinical trial. Through storytelling and sharing their experiences, patients can educate others who are considering a similar journey. In this next video, Melinda Bachini, a 12-year survivor of cholangiocarcinoma discusses her diagnosis and her next steps for dealing with the treatment of this rare cancer. Many thanks to our sponsors! #Exelixis #Novartis #Merck #Lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forums/gall-bladder-and-bile-duct-cancer-cholangiocarcinoma

We are proud to present this series on Clinical Trials Experiences. This unique patient education program gives a voice to patients with experience in participating in a clinical trial. Through storytelling and sharing their experiences, patients can educate others who are considering a similar journey. In this video, Melinda Bachini, a 12-year survivor of cholangiocarcinoma discusses lifting the barriers to entry and acceptance into a clinical trial. Many thanks to our sponsors! #Exelixis #Novartis #Merck #Lilly To join the conversation, https://cancergrace.org/forums/gall-bladder-and-bile-duct-cancer-cholangiocarcinoma For more, please visit http://cancerGRACE.org/.

We are proud to present this series on Clinical Trials Experiences. This unique patient education program gives a voice to patients with experience in participating in a clinical trial. Through storytelling and sharing their experiences, patients can educate others who are considering a similar journey. In this final video, Melinda Bachini, a 12-year survivor of cholangiocarcinoma shares the milestones she has reached, and personal information about the important time that she has been given, because of her ability to participate in a clinical trial. Many thanks to our sponsors! #Exelixis #Novartis #Merck #Lilly To join the conversation, https://cancergrace.org/forums/gall-bladder-and-bile-duct-cancer-cholangiocarcinoma For more,…

We are proud to present this series on Clinical Trials Experiences. This unique patient education program gives a voice to patients with experience in participating in a clinical trial. Through storytelling and sharing their experiences, patients can educate others who are considering a similar journey. In this video series, we talk with Jared Bigman. In the span of almost nine years, Jared has had more than six cancer recurrences and participated in four clinical trials. Many thanks to our sponsors! #Exelixis #Novartis #Merck #Lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

We are proud to present this series on Clinical Trials Experiences. This unique patient education program gives a voice to patients with experience in participating in a clinical trial. Through storytelling and sharing their experiences, patients can educate others who are considering a similar journey. In this video series, we talk with Jared Bigman. In the span of almost nine years, Jared has had more than six cancer recurrences and participated in four clinical trials. Many thanks to our sponsors! #Exelixis #Novartis #Merck #Lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

We are proud to present this series on Clinical Trials Experiences. This unique patient education program gives a voice to patients with experience in participating in a clinical trial. Through storytelling and sharing their experiences, patients can educate others who are considering a similar journey. In this video series, we talk with Jared Bigman. In the span of almost nine years, Jared has had more than six cancer recurrences and participated in four clinical trials. Many thanks to our sponsors! #Exelixis #Novartis #Merck #Lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

We are proud to present this series on Clinical Trials Experiences. This unique patient education program gives a voice to patients with experience in participating in a clinical trial. Through storytelling and sharing their experiences, patients can educate others who are considering a similar journey. In this video series, we talk with Jared Bigman. In the span of almost nine years, Jared has had more than six cancer recurrences and participated in four clinical trials. Many thanks to our sponsors! #Exelixis #Novartis #Merck #Lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Associate Professor of Hematology and Medical Oncology, Associate Professor of Oncological Sciences and Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai Hospital joins us to discuss emerging immunotherapy treatments for B-Cell Non-Hodgkin’s Lymphoma: CAR-T Cells. For this video update, Dr. Joshua Brody gives an in-depth explanation of CAR-T cells and their role in treating Non-Hodgkin’s Lymphoma. Thank you to our sponsors! #karyopharm #pharmacyclics For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forums/blood-cancer.

For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Associate Professor of Hematology and Medical Oncology, Associate Professor of Oncological Sciences and Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai Hospital joins us to discuss emerging immunotherapy treatments for B-Cell Non-Hodgkin’s Lymphoma: Bispecific Antibodies. For this video update, Dr. Joshua Brody discusses the use of bispecific antibodies in the treatment of Non-Hodgkin’s Lymphoma. Thank you to our sponsors! #karyopharm #pharmacyclics For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forums/blood-cancer.

For the GRACE Blood Cancer Video Library, Dr. Aaron Goodman, Associate Professor of Medicine Hematology/Oncology, at Moores Cancer Center, UC San Diego with specialties in Leukemia & Lymphoma, Blood & Marrow Transplant, and Medical Oncology talks about treatment options for Relapsed Diffuse Large B-Cell Lymphoma. For this video update, Dr. Aaron Goodman discusses treatment options for patients who relapse after R-CHOP first-line treatment. Thank you to our sponsors! For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forums/blood-cancer.

For the GRACE Blood Cancer Video Library, Dr. Aaron Goodman, Associate Professor of Medicine Hematology/Oncology, at Moores Cancer Center, UC San Diego with specialties in Leukemia & Lymphoma, Blood & Marrow Transplant, and Medical Oncology, shares information about CAR T-cell therapy. For this video update, Dr. Aaron Goodman explains the process of CAR-T Cell Therapy. Thank you to our sponsors! For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forums/blood-cancer.